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Abstract 
Background: Esophageal adenocarcinoma (EAC) is a deadly cancer with an increasing 
incidence in Western countries during recent decades. Risk factors for EAC include 
obesity, smoking, increasing age, male gender, gastroesophageal reflux disease (GERD), 
and its possible sequel, Barrett’s esophagus (BE). Medical or surgical treatment of GERD 
has not proven protective against EAC. The eradication of BE, combined with reflux 
suppression, is also unable to provide adequate EAC prevention. No long-term results are 
available regarding the effects of the most common BE ablation method, radiofrequency 
ablation (RFA). The origin of BE is still disputed, and despite active research, the 
molecular pathogenesis of EAC remains unknown. Consequently, no clinically validated 
marker molecules exist.  
 
Aims: This study was undertaken 1) to explore the expression of molecules (a disintegrin 
and metalloproteinases, ADAMs) important for cellular signaling, carcinogenesis, and 
inflammation, in GERD and in EAC, 2) to investigate the role of the oncogene CIP2A and 
the associated oncogene c-MYC in EAC and EAC prognosis, 3) to evaluate the long-term 
effects of BE ablation on prevention of carcinogenesis at both the clinical and the 
molecular level, and 4) to assess both the possible reasons for EAC development after 
antireflux surgery and the incidence of EAC after antireflux surgery at population level in 
Finland. 
 
Patients and methods: The possible importance of ADAM molecules for EAC was 
investigated by determining the expression of ADAMs 9, 10, 12, 17, and 19 in esophageal 
cell lines (mRNA and protein levels) and in patient samples at the different stages of 
GERD from esophagitis to EAC compared to samples from normal controls. Molecular 
characteristics of EAC were further investigated in terms of expression of the oncogene 
CIP2A, together with the interrelated c-MYC in EAC patients from two Finnish university 
hospital districts in 1990–2007. Their expression was measured by immunohistochemistry 
in tissue microarray blocks, and correlated with clinicopathologic characteristics and 
prognostic factors. The long-term follow-up of the neosquamous esophageal mucosa and 
the patients’ clinical status was defined in 18 patients after Nd-YAG-laser ablation of BE 
and antireflux surgery during 1992-2005. Prevalence of residual BE was determined, as 
were the properties of the neosquamous epithelium in terms of its oxidative stress, 
intestinal differentiation, and potential for malignancy (p53 expression). EAC occurring 
despite prior antireflux surgery was investigated by identifying all the patients diagnosed 
with EAC and with a previous history of antireflux surgery in Finland during 1980-2006 
(the Finnish Cancer Registry, the National Institute for Health and Welfare, Statistics 
Finland). All of these patient records were evaluated for identifying factors possibly 
associated with the occurrence of EAC after antireflux surgery. The standardized 
incidence ratio of EAC after antireflux surgery was calculated in the Finnish Cancer 
Registry.  
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Results: In EAC cell lines, both ADAM9 mRNA and protein expression was increased. In 
human samples, ADAM9 expression was increased in EAC, and at mRNA level, also in 
BE and BE with dysplasia. All stages from GERD to EAC exhibited changes in ADAM 
expression. The oncogenes CIP2A and c-MYC showed frequent expression in EAC 
(moderate or strong positivity for CIP2A in 78% and for c-MYC in 94%), but neither 
CIP2A nor c-MYC expression was associated with survival.  
At the mean follow-up of eight years after BE ablation with combined antireflux 
surgery, of the 18 patients, macroscopic BE was detectable in 6 (33%) and intestinal 
metaplasia at histology in 8 (44%). The 8-hydroxydeoxyguanosine (8-OhdG) and 
superoxidedismutase (SOD) levels were elevated in the neosquamous epithelium as 
compared to controls’ levels. Myeloperoxidase (MP) activity and glutathione (GSH) levels 
were normal. No abnormal caudal-related homeobox gene 2 (Cdx2)- or p53 expression 
was detectable in the neosquamous mucosa. Of the 1035 EAC patients diagnosed in 
Finland during 1980-2006, previous antireflux surgery had been performed for 53 (5.1%). 
In these patients, BE (45%), endoscopic esophagitis (77%), and hiatal hernia (75%) were 
frequent findings prior to antireflux surgery. Postoperatively, an additional 34% of the 
patients were found to have BE, leading to a histologically confirmed BE diagnosis in 
79%. Patients with an intact fundoplication developed EAC earlier (mean 6.4 years) than 
those with a functionally failed fundoplication (mean 11.2 years). The standardized 
incidence ratio (SIR) for EAC after antireflux surgery was 9.21.  
 
Conclusions: ADAM9 showed the most consistent increase in EAC and in BE. No clear 
progressive increase in a single ADAM was observable during the progressive stages from 
GERD to EAC. ADAMs may participate in the interplay of the signaling networks, also in 
stages before EAC. Their effects, especially those of ADAM9, could be further 
characterized in functional assays. Neither the oncogene CIP2A nor c-MYC predicted 
survival of EAC. 
After BE ablation and antireflux surgery, the recurrence of intestinal metaplasia 
was common, and oxidative signaling was not fully normalized in the long term. The 
neosquamous mucosa did not exhibit markers of intestinalization or malignancy. 
Nationwide, EAC incidence after antireflux surgery remained higher than in the general 
population. EAC often developed late, more than 5 years after antireflux surgery. 
Antireflux surgery does not protect from EAC at population level.  
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1 Introduction 
Esophageal adenocarcinoma is one of the two dominant cancer types in the esophagus. 
Esophageal cancer, the sixth most common cancer as a cause of cancer-related death 
worldwide [1],  is often diagnosed late, with either regional (in 30%) or distant metastases 
(in 40%) already present at diagnosis [2]. Therefore, fewer than 60% of the patients are 
suitable for surgery with curative intention. EAC was once thought to arise from the 
stomach via overgrowth into the esophagus, or from esophageal submucous glands, or 
from ectopic gastric mucosa [3], with only the latter two representing primary esophageal 
adenocarcinomas. The findings of esophageal adenocarcinomas, lined by and separated 
distally from the stomach by columnar esophagus [4], strengthened the idea of primary 
esophageal adenocarcinomas. Norman Barrett, among others, found in the 1950s that this 
columnar lining of the esophagus was histologically different from gastric mucosa [5, 6]. 
The nature of this “Barrett’s esophagus” as an acquired condition or a malformation (a 
vestige of the embryonal endoderm lining the esophagus) was early debated [7].  
Predisposing factors for esophageal adenocarcinoma include obesity, increasing 
age, smoking, male gender, and GERD [8]. GERD causes inflammation of the esophageal 
mucosa (esophagitis), which may turn into columnar intestinal metaplasia (Barrett´s 
esophagus), and later into dysplasia (dysplastic Barrett’s esophagus) and finally into EAC. 
However, only a minority of patients progress from one stage to another [9]. Moreover, 
EAC is often found in those without a diagnosis of GERD or BE [10]. It is thus probably 
the combination of risk factors that leads to EAC development. This combination may be 
assessed both to predict the risk for progression and to plan individualized follow-up and 
treatment.  
GERD is a common complaint presenting with a wide continuum of disease 
severity and variable phenotypes, occurring in 9% to 28% of the population in North 
America and Europe, and in 3% to 33% in Asia [11]. Occasional GERD symptoms are 
experienced by many without GERD. In contrast, a significant proportion of those who are 
asymptomatic present with endoscopic signs of GERD [12]. GERD may be perceived as a 
pathologic continuum of a physiologic disturbance. BE prevalence is 1.6% at population 
level and 6% to 14% in those with GERD [2, 11, 13] Current diagnostic methods, or the 
panel of clinical risk factors, are insufficient in predicting the progression to both EAC 
and Barrett’s dysplasia. Surveillance of Barrett’s esophagus has only recently shown a 
survival benefit [14, 15]. Such surveillance, with appropriate treatment of progression, 
may be cost-effective with a surveillance interval of 5 years in long-segment BE [16].  
To enhance the efficacy of surveillance and treatment, molecular markers to aid in 
tailoring these are essential. To date, no single molecular pathway leading to EAC has 
been found and validated, and clinically useful markers are lacking [17, 18]. A distegrin 
and metalloproteinases, ADAMs, make up a protein subfamily that can activate many 
molecules essential for carcinogenesis and inflammation [19, 20]. Their increased 
expression occurs in many cancers, such as in gastric cancer [20, 21]. Their expression, at 
mRNA level, has also been increased in esophageal adenocarcinoma [22]. Importantly, 
their expression in the stages of GERD preceding EAC, and at protein level, has been 
unknown.  
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One of the few molecules emerging as a promising clinical marker for BE 
progression is p53 [23]. C-MYC, another oncogene with a possible role as a biomarker 
[18], interacts directly with an oncogene CIP2A (cancerous inhibitor of protein 
phosphatase 2A) involved in the phosphorylation cascades important in cellular signaling 
[24]. Overexpression of CIP2A occurs in many cancers, including gastric cancer and 
esophageal squamous cell carcinoma [25-27]. CIP2A expression has also been associated 
with the prognosis of many carcinomas, and with p53 expression [25, 28]. As yet, no 
studies appear to exist concerning the expression of CIP2A in EAC.  
Attempts have been made to eliminate the cancer risk of BE by destroying the 
metaplastic mucosa, together with effectively treating GERD [29]. However, BE tends to 
return in about 12% to 16% of patients in 2 to 3 years after eradication [30, 31]. EAC may 
also appear after the treatment [30, 32], the reasons for which remain unknown. 
Ineffective acid suppression, genetic predisposition, and other risk factors unmodified by 
the treatment are likely to play a role, as well as the possible columnar mucosa hidden 
under the neosquamous epithelium. Given the small cancer risk in nondysplastic BE, the 
ablation of BE is currently reserved for patients with dysplasia or intramucosal cancer, 
with endoscopic resection techniques used first to remove the neoplastic lesions [2, 10].  
GERD can be treated, with symptoms relieved and possible esophagitis healed, 
quite effectively by either medical acid suppression or by surgically enhancing the 
antireflux mechanism of the gastroesophageal junction (GEJ) [11, 33]. Conflicting results 
exist for PPIs in treatment of GERD, regarding risk for EAC, as studied in BE patients 
[34, 35]. For antireflux surgery, small earlier studies preliminarily suggested that 
antireflux surgery might be beneficial in EAC prevention in BE patients [36, 37], yet 
larger studies show that EAC risk after antireflux surgery remains elevated, a risk no 
different from that of nonoperative treatment [38-40]. Many reasons exist for the failure of 
GERD treatment to prevent EAC. GERD alone seems insufficient to cause EAC, and its 
treatment does not remove the effects of other important risk factors. Other proposed 
reasons include the already initiated, irreversible neoplastic transformation, and 
incomplete reflux prevention due to issues such as inadequate medication use or failure of 
antireflux surgery. The absence of GERD symptoms in many patients with ongoing 
harmful reflux is likely to play a role at the population level, as well. EAC risk from BE is 
in fact smaller than previously thought (about 0.1% to 0.3% annually) [10], demanding 
large-scale studies to find any possible effect, and demanding that the other risk factors for 
BE progression should be taken into account.   
EAC nowadays still has a poor prognosis, especially due to the delayed diagnosis 
in the majority of cases, presenting too late for radical cure. Thus, possible means for its 
prevention are essential. The elucidation and understanding of molecular pathways leading 
to EAC could aid both in its prevention and treatment. The present means for EAC risk 
reduction are weight control, cessation of smoking, cure of GERD by life-style factors, 
proton-pump inhibitors, or surgery, and BE surveillance or endoscopic therapy. In this 
study, we assessed the expression of ADAM molecules in GERD and EAC, and the 
expression of CIP2A and c-MYC in EAC and their effect on survival. We also studied the 
possibility of preventing EAC by BE ablation or by antireflux surgery.  
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2 Review of the literature 
2.1 Functional anatomy and histology of the lower esophagus 
and gastric cardia 
During embryogenesis, the esophagus is first lined by columnar epithelium (the 
endoderm), which is replaced by squamous epithelium, starting from the mid-esophagus 
[41]. The adult esophagus contains submucosal glands, concentrated in both the upper and 
the lower esophagus, that secrete substances such as bicarbonate. The epithelium of their 
ducts transforms from cuboidal to squamous cells near the esophageal lumen [42]. 
Landmarks defining the gastroesophageal junction (GEJ) are the squamocolumnar 
junction, the proximal end of the gastric folds, and the distal end of the palisade vessels. 
Normally, these three are situated in approximately the same place [43]. Palisade vessels 
are the longitudinally arranged capillaries situated mainly in the lamina propria, at the 
most distal 2 to 3 cm of the esophagus. Inflammation may obscure their visualization [43, 
44]. Endoscopically, the GEJ is usually defined as the beginning of the gastric folds 
because it is the most reliable landmark.  
The mechanism inhibiting the reflux of stomach contents back into the esophagus 
is multifactorial, and is in GERD often impaired. Gastroesophageal reflux to a certain 
degree is a physiologic phenomenon occurring especially postprandially. The distal 
sphincter mechanism is formed by a 2- to 4-cm long thickened circular muscle layer 
(lower esophageal sphincter, LES), the phrenoesophageal ligaments, crural diaphragm, the 
angle of His, sling fibers of the proximal stomach (cardia), and the intra-abdominal 
location of GEJ [43, 45, 46]. LES is tonically contracted at rest [43, 47]. When LES 
relaxes, the longitudinal esophageal muscle contracts, and the gastric cardia rises upwards 
[48]. The phrenoesophageal ligaments are fascial elastic structures that insert 
circumferentially into the distal esophagus, close to the squamo-columnar junction (SCJ), 
from the diaphragmatic hiatus. They bring the GEJ back into place after it has risen during 
LES relaxation, for instance, in swallowing [43]. The right crus of the diaphragm is also 
important in assisting LES in that it contracts during LES relaxation and at times of 
increased intra-abdominal pressure [43, 48]. The sling fibers of the cardia also participate 
in the sphincter mechanism [45].  
The location and definition of the gastric cardia have been debated, and also its 
nature as a congenital anatomic entity or an acquired metaplastic lesion. It lies directly 
distal to the gastroesophageal junction, and its glands secrete mucus, but do not contain 
parietal or chief cells (characteristic of the gastric oxyntic mucosa) and consequently do 
not secrete acid or pepsinogen [49]. Studies in children, fetuses, and embryos show 
evidence of the gastric cardia as a congenital structure already developing during 
pregnancy, with a length of 0.3 to 4.0 mm [50-52]. Cardiac epithelium has appeared in the 
GEJ in 67% of those older than 15 years undergoing upper gastrointestinal endoscopy 
[53]. The histological definition of GEJ has been proposed to be the proximal limit of the 
gastric oxyntic mucosa [54].  
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2.2 Gastroesophageal reflux disease (GERD) 
2.2.1 The pathophysiology of GERD 
The principal reflux mechanism in patients with normal GEJ anatomy – who also tend to 
have a milder form of GERD - is transient relaxations of the LES (TLESR) [43]. TLESRs 
occur independent of swallowing due to the distension of the stomach, especially the 
fundus, and they are normal during digestion and belching [43]. In GERD, reflux-
associated, but not the total number of TLESRs, are increased [48]. Other mechanisms 
producing pathologic reflux include decreased LES pressure, anatomic disruption of the 
GEJ, impaired esophageal clearance due to weak or absent esophageal peristalsis [43, 48], 
and possibly delayed gastric emptying [55]. The angle of His, or the esophago-gastric 
insertion angle, is more obtuse in GERD patients than in control subjects [45]. Moreover, 
in GERD, the post-prandial acidic environment in the GEJ, the acid pocket or intra-
sphincteric reflux, extends more proximally [48]. The level of gastric acid secretion is not 
elevated in GERD, nor does it relate to the severity of esophagitis [56].  
Anatomic disruption of the GEJ may lead to a hiatal hernia, which predisposes to 
GERD through the altered GEJ physiology, including loss of its intra-abdominal location, 
loss of crural contraction, and loss of the normal angle of His. Hiatal hernias also impair 
esophageal acid clearance [43]. Of the four types of hiatal hernias, type I hiatal hernia is a 
sliding hiatal hernia accounting for 85% to 95% of all cases [57]. Hiatal widening 
(looseness of the right crus) and laxity of the phrenoesophageal ligaments allow the 
herniation of the GEJ and the proximal part of the stomach into the thoracic cavity [43]. 
The GEJ normally moves within 2 cm up- and downwards during swallowing, so a sliding 
hernia can be diagnosed when the movement is > 2 cm. [43]. Types II to IV (5-15%) are 
paraesophageal hernias. In type II, the gastric fundus herniates through the hiatus; type III 
has both a sliding hernia and a paraesophageal gastric fundic component; and in type IV, 
other abdominal organs herniate into the thoracic cavity [43, 57]. 
2.2.2 Epidemiology of GERD 
The Montreal classification defines GERD as a disease in which the refluxed gastric 
contents cause troublesome symptoms or complications [58]. Many people experience 
occasional GERD symptoms without actually having the disease, while a significant 
number of patients with GERD are asymptomatic. The prevalence of GERD, defined as at 
least weekly heartburn or regurgitation, or both, ranges from 2.5% to 33.1% depending on 
geographic area, with a prevalence of 8.8% to 25.9% in Europe, and with even higher 
numbers in North America [11]. The incidence of GERD has been rising in western 
countries since 1995 [11], along with GERD-associated mortality [59]. GERD incidence 
in the UK and USA is approximately 5.0 per 1000 person-years [11]. Its incidence in 
children has also been increasing, for example in the USA by 30% to 50% during 2000-
2005 [60].  
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2.2.3 GERD symptoms  
The main GERD symptoms are heartburn and regurgitation. GERD may, however, present 
also with chest pain, dysphagia, or extraesophageal symptoms such as cough, laryngitis, 
asthma, and dental erosion [58] as well as hoarseness, throat-clearing, and wheezing [61]. 
Questionnaires can serve for GERD evaluation [62]; these include health-related quality-
of-life questionnaires. Approximately 40% of patients with GERD symptoms have 
endoscopic esophagitis [63]. In contrast, of the patients with erosive esophagitis in Asia, 
43% to 59% have been found to be asymptomatic [12, 64]. The severity of GERD 
symptoms, although correlating in part with endoscopic findings, does not predict the 
degree of esophagitis or esophageal metaplasia [58].  
2.2.4 Endoscopic classification and severity of GERD   
GERD is classified into erosive reflux disease (ERD) with visible endoscopic changes 
versus non-erosive reflux disease (NERD) without endoscopic changes. Symptom-
correlation with acid reflux distinguishes NERD from functional heartburn [65, 66]. 
Endoscopic findings in ERD are most often classified according to the Los Angeles 
grading system, in which esophagitis is graded both by length and extension of the 
mucosal breaks over the mucosal folds [67]. In grade A, the distinct mucosal breaks are ≤ 
5 mm; in grade B, they are > 5 mm; in grade C, the mucosal breaks are continuous and 
involve < 75% of the esophageal circumference; in grade D, the continuous mucosal 
breaks involve more than 75% of the circumference [67]. Barrett’s esophagus (BE) and 
esophageal strictures are considered complications of ERD [58]. The significance of 
esophagitis detected only histologically, microscopic esophagitis, is unknown. It has, 
however, recently been detected only in patients with GERD and not in those with 
functional heartburn [68].  
Several studies have demonstrated that increasing acid reflux is associated with 
more severe GERD, increasing from NERD to progressive stages of ERD. Lower LES 
pressure, ineffective esophageal motility, and a higher prevalence of a hiatal hernia also all 
increase with more severe GERD [69-71]. Bile reflux also increases in ERD and in BE 
[63]. Patients with ERD have shown male predominance (58% vs. 40%), higher BMI, a 
tendency to be older, and a more frequent occurrence of a hiatal hernia than did those with 
NERD, whereas no difference appeared in symptom duration [72]. A hiatal hernia is 
frequently found in patients with reflux esophagitis (50-94%), and in patients with BE 
(72-96%) when compared to 13% to 59% in normal controls [43].  
2.2.5 Other diagnostic methods 
In addition to symptom assessment and upper gastrointestinal endoscopy with biopsies, 
other diagnostic tools for GERD are pH-monitoring, manometry, and impedance testing. 
In 24-h pH-monitoring, esophageal acid exposure is measured with an electrode that 
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records acid reflux. The electrode is inserted transnasally to 5 cm above the LES and 
connected to an external recorder. There is also a wireless pH-probe option [62]. The 
number and duration of the reflux events are documented, with reflux during upright and 
supine positions distinguished. A pH < 4 is considered the threshold discriminating 
between physiological and pathological gastro-esophageal reflux episodes. Most often, the 
total percentage of time that pH is < 4 is reported, with normal values being ≤ 4 to 5.5% 
[73]. Symptoms occur during only 10% to 20% of all acid reflux events [73].  
Manometry assesses esophageal motility, peristalsis, contractions, and LES 
pressure. In GERD evaluation, it may serve to exclude other conditions, and to aid in 
classifying the motility and pressure abnormalities of GERD, such as TLESRs and the 
LES pressure [62, 74]. A more precise application, high-resolution manometry, is better at 
characterizing TLESRs [74].  
Impedance testing measures the electric resistance between electrodes positioned 
along the length of the esophagus on a catheter. It can detect and discriminate gas reflux 
from liquid reflux. The multiple-electrode system allows determination of the extent of 
reflux in the esophagus. Combined with pH-monitoring, the relationship of reflux of 
differing acidity can be measured and correlated with symptoms. With impedance testing, 
pH-monitoring, and manometry in combination, the sensitivity and specificity for GERD 
diagnosis are both over 90% [75].  
2.3 Barrett’s esophagus (BE) 
2.3.1 BE definition 
Barrett’s esophagus (BE) is a condition in which metaplastic columnar (intestinal) mucosa 
has replaced part of the squamous mucosa of the distal esophagus (Figure 1). It is defined 
as an endoscopically visible esophageal columnar mucosa confirmed histologically [10], 
and frequently, with the evidence of intestinal-type goblet cells as evidence of intestinal 
metaplasia. In the UK and Asia, however, intestinal metaplasia is not required for the 
diagnosis of BE [13]. Other types of columnar epithelium that may occur in the 
metaplastic distal esophagus are of the gastric fundic and cardiac types [76]. The 
association between EAC and BE has been based on evidence of intestinal metaplasia 
(IM) [13, 77]. IM may also be patchy, requiring extensive sampling, and may thus be 
underdiagnosed [77]. However, also the cardiac type epithelium seems to carry a risk for 
EAC, although the magnitude of this risk is unknown, and controversy exists [76, 77]. The 
presence of cardiac epithelium is associated with features of GERD [53], and cardiac IM 
may be a condition preceding BE [78]. Multilayered epithelium at the gastroesophageal 
junction poses features of both columnar and squamous epithelia, but is of unknown 
significance [41]. 
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Figure 1 Endoscopic image of Barrett’s esophagus. GEJ = gastroesophageal junction 
(Photograph by Henna Söderström) 
The Prague criteria are the most-used criteria for endoscopic definition of BE 
extent. According to these criteria, BE length is defined as the circumferential extension 
(C, in centimeters) and the maximal (M, in centimeters) extent of the metaplasia proximal 
to the GEJ [79]. BE can also be classified by its length (Table 1).  
Table 1 Classification of BE according to length. GEJ = gastroesophageal junction 
 
 
 
 
 
2.3.2 BE epidemiology 
At population level in Sweden, BE has been found in 1.6% of adults [80]. In the same 
study, columnar-lined esophagus occurred in 8.3% [80]. In patients with symptomatic 
GERD, BE has been diagnosed in 14.1% and columnar-lined esophagus in 23.3% [13]. 
Other studies have reported BE in 6% to 12% of patients with longstanding GERD 
symptoms [2].  
Type of Barrett's esophagus Length above the GEJ 
long-segment ≥ 3 cm 
short-segment ≥ 1 cm, < 3 cm 
ultra-short-segment < 1 cm 
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2.3.3 The origin of BE 
BE is nowadays considered an acquired rather than a congenital condition. Causes and 
mechanisms leading to the replacement of normal esophageal squamous epithelium with 
columnar, mucus-secreting epithelium need clarification. Possible mechanisms include 
either mature esophageal squamous cells or immature progenitor cells turning into 
columnar cells, or stem cells from the bone marrow, gastric cardia, or gastroesophageal 
junction giving rise to the metaplastic epithelium [10]. The possible presence of 
multipotent stem cells’ changing their commitment could explain the different types of 
columnar esophageal epithelia in GERD. The location of these possible stem cells inside 
or outside the mucosa (such as in submucosal gland ducts) remains unknown [41]. 
Recently, however, BE stem cells capable of long-term self-renewal have been grown 
from BE biopsies. These stem cells differed from cells grown from the squamous 
esophagus, or from the stomach [81]. 
2.4 Risk factors for GERD, BE, and esophageal adenocarcinoma 
(EAC) 
GERD, BE, and EAC share similar risk factors. Importantly, GERD predisposes to BE 
and EAC. Symptomatic GERD is a risk factor for BE [82], and young age at the onset of 
GERD symptoms elevates BE risk [83]. Bile reflux is increased in BE [70, 84], and bile 
acids induce BE in rats [85]. For EAC, at least weakly symptoms of heartburn and/or 
regurgitation confer a 4.8- to 7.7-fold risk, a risk dependent both on duration and 
frequency of symptoms [86, 87]. Individuals suffering from at least weekly symptoms for 
at least 20 years had a 9.3-fold risk (odds ratio, OR) for EAC in a meta-analysis of case-
control studies, whereas those with severe symptoms (a score based on the symptom type 
and frequency) for at least 20 years had a 44-fold risk for EAC in a case-control study [86, 
87]. Nocturnal symptoms were associated with an over 10-fold risk for EAC [87]. Reflux 
symptoms are similarly associated with EAC in both BE patients and those without 
diagnosed BE [87]. Of patients undergoing esophagectomy for EAC, 22% had a history of 
reflux in one population-based study [88], whereas 64% reported a history of GERD 
symptoms in a single-center study [89].  
BE is a risk factor for EAC. The reported proportion of EAC patients with a 
previous diagnosis of BE varies, ranging from 1.3% to 7.2% in population-based studies 
[14, 88] to about 5% to 34% in patients undergoing surgical resection for EAC [89, 90]. 
EAC risk increases with increasing length of BE [91]. A previous diagnosis of BE seems 
to be associated with lower tumor stage, milder histology, and enhanced survival [14]. 
During EAC diagnosis, BE may have disappeared due to overgrowth. In a study with an 
IM prevalence of 45% in junctional or cardiac, and 87% in distal esophageal tumors, IM 
was present in all tumors with diameter < 1 cm, and in all intramucosal tumors; IM 
prevalence decreased with increasing disease stage. [92]. 
Increasing age and male gender are risk factors for both BE and EAC [1, 10]. 
Obesity is a risk factor for GERD and subsequent metaplasia, dysplasia, and neoplasia 
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[10, 62]. Abdominal obesity in particular predisposes to erosive esophagitis, BE, and EAC 
[93]. EAC risk increases with rising body-mass index (BMI) [94]. The risk may be 
conferred by abdominal obesity, because it remains a risk factor when controlling for BMI 
and not vice versa [93, 95], and even in normal-weight individuals [96]. The increased risk 
may be due to increased reflux because of the increased intragastric pressure impairing 
GEJ function, or independently of GERD due to visceral fat-secreting pro-inflammatory 
cytokines [97]. Increased leptin levels and insulin resistance are associated with increased 
EAC risk in BE patients [98]. The risk of abdominal and general obesity for BE and EAC, 
respectively, seems independent of GERD [93, 94]. Importantly, obesity and GERD seem 
to cause increased EAC risk additively [94]. Smoking confers about a 2-fold risk for EAC, 
with the magnitude of risk depending on both dose and duration of smoking [99, 100]. 
Smoking is also a risk factor for GERD and BE [10, 62].  Alcohol may be a risk factor for 
BE in men and in Asians [101]. It is not a risk factor for EAC, however, although alcohol 
predisposes to the other important esophageal cancer type, squamous cell carcinoma [2]. 
There are genetic susceptibility loci of mutated genes for BE and EAC [102], 
hinting at a genetic predisposition. Genetic risk factors may interact with environmental 
factors such as GERD and smoking in contributing to EAC [103]. Familial clustering 
occurs in about 7% of BE and EAC cases, with EAC occurring at a younger age than 
usually [104]. The suggested inheritance type is autosomal dominant, but environmental 
factors may also play a role [105]. Race affects EAC risk: EAC incidence is low in Blacks 
and high in Hispanics, as compared to Caucasians [106], in whom BE is the most 
prevalent [107]. 
An inverse relationship exists between Helicobacter pylori (H. pylori) infection 
and risk for both EAC and BE. The possible protective role of this infection may be due to 
decreased gastric acidity [108]. In rats, esophageal H. pylori colonization elevated the 
severity of esophagitis and induced markers of BE and proliferation, however [109]. In 
addition, low vegetable- and fruit intake seems to be a risk factor for EAC [110], whereas 
high fiber intake reduces risk for EAC and BE. The risk-lowering effect of a high-fiber 
diet may be due to anti-proliferative and anti-inflammatory agents that this kind of diet 
contains [111]. LES-pressure-lowering medication seems to be a risk factor for EAC, 
probably by causing increased reflux [112]. These kinds of drugs, ones such as nitrates 
and anticholinergics, are also risk factors for GERD [62]. Non-steroidal anti-inflammatory 
drugs (NSAIDs) and statins are associated with reduced EAC risk [113-115]. Statins also 
reduce risk for BE [116]. Whether the mechanism of NSAIDs in preventing EAC is their 
anti-inflammaroty properties is unclear. The effect of statins might be explained by their 
anti-proliferative action [114].  
A possible role for female hormones explains in part the age- and gender 
associations of EAC. EAC incidence has been measured as 7.7-fold higher in men than in 
women [117]; also in BE patients, EAC incidence is higher in men [118]. The male-to-
female incidence ratio is highest at ages 50 to 54 [117] or 50 to 59 [106], and in each 
study, declines after that. Hormone replacement therapy and oral contraceptives seem to 
reduce EAC risk [119]. At cell-line level, estrogen and selective estrogen receptor 
modulators have been shown to reduce growth in both EAC and BE cell lines, and in EAC 
cell lines they stimulate apoptosis [120]. 
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2.5 Endoscopic surveillance of BE 
Current guidelines suggest endoscopic surveillance for nondysplastic BE at intervals of 3 
to 5 years [10]. The cost-benefits of endoscopic surveillance have, however, been 
questioned because of the rarity of EAC’s being detected in surveillance (0.63% annually) 
and the low mortality (0.3% annually) in a meta-analysis [121]. By surveillance, cancers 
may be detected at an earlier stage and thus have a better prognosis [122], yet surveillance 
has also failed to show any impact on EAC mortality [123]. Recently, patients with a prior 
BE diagnosis have shown enhanced survival, and tumors have been of earlier stage and of 
lower histological grade with enhanced operative resectability [14]. A large prospective 
cohort study showed excellent results for BE (≥ 2 cm) surveillance; EAC was diagnosed at 
an earlier stage and with a survival not significantly differing from that of BE patients 
without cancer development (although the 5-year survival-rates were 74% vs. 94%, 
respectively), and similar to survival of stage 0- to 1 tumors detected in the general 
population [15]. Thus, although the cancer risk in BE is lower than previously estimated, 
surveillance may lead to survival advantage. Recent analysis suggests a less frequent 
surveillance protocol to be cost-effective: a surveillance interval of 5 years for long-
segment BE without dysplasia and 3 years for long-segment BE with low-grade dysplasia 
[16]. However, the European Society of Gastrointestinal Endoscopy recommends a 
surveillance interval of 5 years for short-segment BE and of 3 years for long-segment BE 
(up to 10 cm, otherwise referral to a specialized center) [124]. To enhance the efficacy of 
surveillance, the protocols could be tailored also taking into account other associated risk 
factors, like obesity, smoking, and age. 
2.6 Barrett’s dysplasia 
The neoplastic transformation of Barrett´s metaplasia into EAC occurs through dysplastic 
changes. According to the Vienna classification, non-invasive intra-epithelial neoplasia 
comprises low-grade dysplasia (LGD), high-grade dysplasia (HGD), carcinoma in situ, 
and suspicion of invasive carcinoma. A lesion is classified as indefinite for dysplasia if its 
true nature is undetermined. The distinction between low-grade and high-grade dysplasia 
should correspond to risk for invasion [125]. This dysplasia grading applies well to 
Barrett’s dysplasia, with the aid of p53 expression in the prediction of progression [126].  
Histologically, LGD presents with nuclear polarity and mild changes in the appearance of 
the nuclei and potential glandular crowding. In HGD, the mucosal surface and glands are 
distorted, glandular crowding is present, the lamina propria is sparse, and the nuclei 
display many pathologic changes such as hyperchromasia, enlargement, and 
pleomorphism [127]. Dysplasia can also be morphologically characterized into 
adenomatous and foveolar types, and a combination of these, with a potential importance 
for carcinogenesis [128]. The detection and classification of dysplasia is complicated, as 
dysplastic spots may be patchy and invisible. The histologic characterization with varying 
depths of tissue biopsies is subjective, with distinct inter-observer variance. Inflammation 
and regeneration produce changes that can be hard to distinguish from dysplasia, and that 
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may hamper its grading. The diagnosis of dysplasia needs confirmation by an expert 
pathologist. Healing of esophagitis by medical treatment may help in distinguishing 
regenerative atypia from true dysplastic lesions [129]. Indeed, the incidence of regression 
from LGD to non-dysplastic BE has been 57% annually [16]. For increased accuracy of 
dysplasia classification and detection in BE surveillance, the metaplastic epithelium 
should be biopsied at 2-cm intervals from four sides of the esophageal lumen. If dysplasia 
has been previously detected, the biopsies should be taken at 1-cm intervals [129]. 
2.7 Risk for progression of BE and associated dysplasia 
In patients with BE, EAC risk has, according to recent studies, been much lower than 
earlier suggested [118, 130]. The EAC incidence in BE is 0.29% to 0.43% annually, and 
when excluding cancers diagnosed less than one year after the initial BE diagnosis, EAC 
incidence in BE is 0.12% to 0.18% annually [118, 130-134]. According to one meta-
analysis, short-segment BE also carries an annual 0.19% EAC risk [134]. Recently, annual 
cancer transition rates for differing lengths of BE were estimated to be 0.22% for long-
segment BE, 0.03% for short-segment BE, and 0.01% for ultra-short-segment BE [91]. 
The incidence of LGD has been 3.6% to 5.7% annually, but the true transition rate was 
estimated at 2.3% annually [16, 133]. The incidence of HGD in BE has been 0.48% 
annually [133]. 
BE with LGD carries a 0.54% annual risk for EAC according to a meta-analysis, 
with the risk ranging from 0.02% to 11.4% across studies [135]. The incidence of either 
HGD or EAC in LGD was 1.73% annually (range 0.04%-26.7%) [135]. A recent 
prospective cohort study found the incidence of HGD or intramucosal EAC in LGD to be 
13.1% annually, but the true annual transition rate was estimated to be lower, at 4.3% [16]. 
In BE with HGD, the annual EAC incidence in another meta-analysis was 5.6% [136]. In 
patients with HGD in pre-treatment biopsies, EAC confined to the mucosa or submucosa 
occurred in 52% of the endoscopic resection specimens. Most of the upgraded cases 
presented with a visible lesion at endoscopy [137]. In patients undergoing esophagectomy 
with a preoperative HGD diagnosis, the rate of upgraded cases has been lower, with EAC 
detectable in 17.6% [138]. 
2.8 Treatment of Barrett’s dysplasia 
All visible lesions in BE, irrespective of dysplasia grade, should always be removed by 
endoscopic resection [124] prior to possible ablation. If LGD is detected in random 
samples, and the diagnosis is confirmed, acid suppression treatment by proton pump 
inhibitors (PPIs) to heal esophagitis is recommended before follow-up endoscopy at 6 
months [124, 129]. According to the guidelines of the European Society of 
Gastrointestinal Endoscopy, if the diagnosis remains LGD after the PPI therapy, the 
patient should receive endoscopic ablation. If LGD has disappeared, surveillance 
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endoscopies should be performed first at 12-month intervals. For HGD without visible 
pathology, endoscopic ablation is necessary [124]. 
2.9 Esophageal adenocarcinoma 
2.9.1 Diagnosis of EAC 
The most common symptom of esophageal cancer is dysphagia. Other symptoms include 
weight loss, fatigue, and anemia [8]. Diagnosis is made by upper gastrointestinal 
endoscopy and histology. Esophageal carcinoma is classified into five main stages 
according to the TNM classification [139]. Computed tomography, 18F-
fluorodeoxyglucose positron-emission tomography (FDG-PET), endoscopic 
ultrasonography, and bronchoscopy (mid-thoracic tumors) are means for determining 
disease stage [1]. 
Esophageal cancer is classified according to its location: cancer in the cervical 
esophageal (C15.0), intrathoracic esophageal (C15.3, upper-; C15.4, mid-; and C15.5, 
lower thoracic portions), or esophagogastric-junction cancer (C16.0) [139]. EAC is most 
often situated in the distal esophagus. 
2.9.2 EAC incidence 
In Western countries, the incidence of EAC has been rising and even exceeding that of the 
worldwide-predominant squamous cell carcinoma in areas such as the USA, the UK, and 
Finland [1]. The rate of increase has, however, fallen in recent years [140, 141]. 
Contradictory results exist as to the similarity of the increasing rates in men and women. 
The mean increase in EAC incidence from 1975 to 2009 was almost the same for both 
sexes, 6.1% per year for men and 5.9% per year for women in the USA (average annual 
percentage change), with another study reporting annual positive percentage change 
higher for men, however [117, 141]. A shift has occurred in the stage distribution of EAC, 
with the proportion of local disease slightly increased and that of distant disease slightly 
decreased [142].  
2.9.3 Treatment of EAC 
Treatment methods for esophageal cancer, depending on disease stage, include endoscopic 
mucosal resections (with ablation of the BE), esophagectomy with or without neoadjuvant 
treatment, and chemoradiotherapy, as well as palliative procedures (such as stents, 
gastrostomy, jejunostomy). Endoscopic resection is commonly accepted for cancerous 
growth confined to the epithelial cells (carcinoma in situ), and for intramucosal T1-tumors 
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(T1a) [2]. However, the risk for lymph node spread (N1) in intramucosal T1-tumors has 
been 7% [143]. T1b tumors that extend into the submucosa may have lymph node 
metastasis in up to 20% of cases [2]. Tumors with superficial submucosal invasion (T1b 
sm1) may be treated with esophagectomy or endoscopic resection in selected cases. 
Endoscopic treatment may be appropriate for patients at an increased risk for operative 
complications, especially for well-differentiated tumors without lymphovascular invasion. 
Endoscopic ultrasonography may aid in evaluating the lymph node status in these T1b 
tumors. For tumors with deeper submucosal invasion (T1b sm2-3), esophagectomy should 
be performed, and endoscopic treatment remains a palliative option for patients unfit for 
surgery [129].  
Esophagectomy is the treatment of choice for locally advanced EAC. It may be 
performed either via an open approach or mini-invasively by thoracosopy and 
laparoscopy. There are several options for open esophagectomy: the Ivor-Lewis procedure 
with thoracic and abdominal incisions, transhiatal esophagectomy with abdominal and 
neck incisions, and a combination of neck, thoracic, and abdominal incisions [8]. The 
removed portion of the esophagus is replaced most often by tubularized stomach pulled 
into the chest. A segment of colon or jejunum may also be used. For tumors with distant 
metastasis, palliative procedures are used, and chemoradiation or chemotherapy. 
Immunologic agents are also under assessment [1]. 
2.9.4 Lymph node retrieval and chemoradiotherapy 
The number of lymph nodes removed in surgery is important for the cure and prognosis of 
the disease and also for evaluation of adjuvant treatment. Controversy exists about the 
need for two-field lymphadenectomy comprising nodes in the abdomen and chest or three-
field lymphadenectomy including also lymph nodes in the neck. In Western countries, 
two-field lymphadenectomy is common. Three-field lymphadenectomy may result in an 
increased number of complications without a survival advantage [1]. Both an increased 
and decreased number of retrieved lymph nodes have been reported in minimally invasive 
esophagectomy (MIE) as compared to open surgery [144, 145]. The indications, optimal 
timing, and the method (chemotherapy with or without radiotherapy) of adjuvant therapy 
for EAC are not yet clear. Neoadjuvant treatment is used for ≥ T3 or ≥ N1 disease [146]. 
In clinically staged T2 tumors, about half the patients have lymph node metastasis, 
suggesting the benefit of neoadjuvant treatment [147].   
2.9.5 Complications of surgery 
The 30-day morbidity rate of surgery is as high as 50% to 60% in locally advanced 
disease, and the 30-day mortality rate is 2% to 4% [144, 145].  Complications include 
pneumonia, empyema, cardiac complications, anastomotic leak, conduit necrosis, and 
vocal cord palsy [144]. 
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Minimally invasive esophagectomy has been comparable to open esophagectomy 
in terms of mortality, but the hospital stay after MIE is shorter [144, 145]. After MIE, 
complication rates and 5-year-survival rates are similar with open esophagectomy [144]. 
2.9.6 Survival of EAC 
Esophageal cancer spreads early, due to both the lack of visceral peritoneum (serosa) in 
the esophagus and extensive lymphatic drainage to both thoracic and abdominal nodes 
originating in both the esophageal mucosa and the muscularis layers [146]. In addition, 
EAC also spreads hematogenously. At diagnosis, 30% of the tumors already display 
regional metastasis, and 40% display distant metastasis [2].   
The 5-year survival rate of esophageal carcinoma is only 15% to 25% [1], with a 
slightly higher survival rate for EAC than for squamous cell carcinoma [2]. Survival has 
improved over recent decades especially in those patients treated with surgical resection 
[142]. Survival depends on disease stage at diagnosis [1]. In superficial EAC (pT1N0-1, 
M0), the 5-year survival is 67%, and in locally advanced EAC (stage IIb-IIIc), 41% after 
minimally invasive esophagectomy and 56% after open esophagectomy [144, 148]. 
Locally advanced EAC, resected surgically after neoadjuvant treatment with a complete 
pathologic response (ypT0N0M0R0), leads to a 5-year survival of 55%, with the disease-
specific survival rate being 68% [149]. In distant (stage IV) esophageal carcinoma, the 5-
year survival is 6% [150] .  
Incidence-based mortality from EAC seems to be rising less steeply than is EAC 
incidence. In the 21st century, incidence-based mortality in local EAC may even have been 
slightly declining, while in regional EAC it seems to have nearly stabilized, but in distant 
disease it has kept rising [141]. 
2.10 Adenocarcinoma of the gastroesophageal junction 
The definition of the origin of cancers located near the GE junction is difficult due to 
tumor overgrowth and the histologic similarity of these adenocarcinomas. They may arise 
from three different sources (from the mucosa of the esophagus, from the gastric cardia, or 
from the stomach below). In addition, the lack of consensus regarding the gastric cardia 
adds variability to the definition of these cancers. Adenocarcinoma around the 
gastroesophageal junction has been classified morphologically by Siewert into tumors 
originating in the distal esophagus, true cardia carcinomas, and tumors originating in the 
proximal stomach [151]. The present classification [152] is in Table 2.  
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Table 2 Classification of adenocarcinoma of the gastroesophageal junction (GEJ)  
Type Epicenter in relation to GEJ Invasion to GEJ 
I 1-5 cm above yes / no 
II 1 cm above to 2 cm below yes 
III 2-5 cm below yes 
 
Histologically, IM is a common finding also in tumors with their epicenter at or 
below the esophagogastric junction, although less common than in distal esophageal 
tumors (45% vs. 87%) [92]. The risk factors for gastroesophageal junction 
adenocarcinomas are much like those of EAC: smoking, GERD, obesity, and nutritional 
factors. Helicobacter pylori infection and the use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) are associated with a reduced risk for this cancer. Except for smoking, the 
association of the risk factors is weaker than for EAC [153]. GERD entails a smaller risk 
for gastroesophageal junction adenocarcinomas than for EAC [40, 87, 154]. At least 
weekly symptoms of heartburn or regurgitation confer a 2.0- to 2.3-fold risk for junctional 
adenocarcinomas; the frequency and duration of symptoms show a much weaker 
association with GEJ cancer risk than with EAC [86, 87]. The incidence of 
adenocarcinomas of the GEJ increased until the beginning of the 1990s, but stabilized 
after that in the USA, unlike the incidence of EAC [153]. 
2.11 Treatment of GERD 
The aim of GERD treatment is to relieve symptoms and heal esophagitis. The presence of 
a sliding hiatal hernia does not change the treatment protocol, because its treatment is also 
based on symptoms of GERD or complications such as ulcerations [43]. 
2.11.1 Lifestyle changes 
The basis of conservative treatment is lifestyle changes to relieve symptoms, although 
their efficacy has not been well documented [11]. These include avoiding symptom-
provoking food, slow eating to avoid concomitant air ingestion, eating at least two hours 
before going to bed, and sleeping with the upper body slightly raised to avoid supine 
reflux, and also weight reduction. Avoiding the risk factors of GERD, such as smoking 
and LES-relaxing medication, is also recommended. 
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2.11.2 Medical treatment 
The most common and primary treatment method for GERD is medical treatment. For 
mild or post-prandial symptoms, the choice may be antacids or alginate. Antacids are 
drugs that neutralize acid, and alginate is a water-binding colloid that forms a viscous gel 
in the stomach [11]. When more efficient treatment is required, gastric acid secretion can 
be reduced by proton pump inhibitors (PPIs) or histamine2-receptor antagonists (H2RAs). 
PPIs reduce esophageal acidity more effectively than do H2RAs [155], and are superior to 
H2RAs in healing esophagitis, due to their longer effect on pH rise [73]. PPIs may also 
lead to the regression of BE length and area [155]. Their long-term use has suggested side-
effects, such as predisposition for osteoporotic fractures and fundic gastric polyps [156]. 
 Other drugs that may be useful in GERD are prokinetics such as metoclopramide, 
and drugs that relieve esophageal hypersensitivity such as tricyclic antidepressants or 
selective serotonin reuptake inhibitors [11].  
2.11.3 Surgical treatment 
2.11.3.1 Indications 
Antireflux surgery is indicated for patients who continue to suffer severe reflux symptoms 
despite maximal medical treatment. GERD must be documented objectively by methods 
such as upper gastrointestinal endoscopy, pH-monitoring, or esophageal manometry [157]. 
Preoperative symptomatic response to PPI therapy may aid in evaluation of the probable 
surgical outcome. Patients with a good response to PPI therapy have better symptomatic 
relief after antireflux surgery than do non-responders [158].  
2.11.3.2 Antireflux surgery techniques 
The aim of antireflux surgery is to repair the anatomic and physiologic disturbances of the 
GEJ that cause GERD. This includes creation of a valve that compresses the 
esophagogastric junction area, leading to an increase in LES pressure, as well as in 
esophageal peristaltic amplitude and frequency [159, 160], and leading to re-establishment 
of the angle of His. An essential part of antireflux surgery is hiatal hernia repair and 
closure of a possible hiatal defect [161]. Fundoplication (Figure 2) is the gold standard of 
antireflux surgery and has been shown to reduce the rate of TLESRs, their association 
with reflux, and the distensibility of the GEJ, even > 5 years postoperatively, when 
compared to the situation in GERD patients without surgery [162]. 
In fundoplication, the fundus of the stomach is wrapped around the lower portion 
of the esophagus and sutured to construct a 360° plication around the GEJ area and the 
esophagus (a total wrap), or is sutured into the esophagus and surrounding structures (a 
partial wrap of 90-270°). The 360° total Nissen fundoplication, or its modified version 
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[163], is the most common antireflux procedure. A partial wrap may be constructed either 
anterior to (as in Thal, Dor, and Belsey Mark IV fundoplications) or posterior to (as in 
Toupet fundoplication) the esophagus [157, 161]. The superiority of a total or partial 
wrap, in terms of reflux control and adverse effects (dysphagia, gas-bloat syndrome), is 
still debatable. Meta-analyses have shown that laparoscopic partial fundoplication results 
in less postoperative dysphagia and gas-related symptoms than does the laparoscopic 
Nissen fundoplication, whereas reflux control seems essentially equal – with the exception 
of a finding of reduced heartburn after the Nissen operation in one meta-analysis [164-
166].  
 
 
Figure 2 Endoscopic image of an intact fundoplication wrap. (Photograph by Markku 
Luostarinen)  
Apart from fundoplication, partial gastrectomy with vagotomy and Roux-en-Y 
reconstruction is a method for reducing both acidic stomach secretion and bile reflux. 
Together with an antireflux procedure (fundoplication or Hill’s gastropexy), it may lead to 
the regression of BE to the cardiac mucosa [167, 168]. Gastric bypass with a Roux-en-Y 
reconstruction in the obese may also result in BE regression [168]. These procedures 
(Roux-en-Y reconstruction combined with either fundoplication or Hill’s gastropexy, 
antrectomy, and vagotomy, or with resectional gastric bypass) also show effective reflux 
control [167, 168]. New experimental techniques have also been introduced as alternatives 
to fundoplication in the treatment of GERD. A magnetic band placed around the GEJ (the 
LINX prosthesis) has initially shown promising results [169]. There also are endoscopic 
procedures aiming at plicating the stomach, with promising results in terms of diminished 
PPI use for the transoral EsophyX device at the 2-year follow-up [170]. Other techniques, 
such as laparoscopically implanted electrodes to stimulate LES, have also shown initially 
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promising results in subjective outcome as well as in pH-monitoring [171]. No studies 
cover the long-term durability and effectiveness of these new techniques.  
2.11.3.3 Results 
Antireflux surgery offers good relief of reflux symptoms in the majority of patients (77-
92%) [33, 172]. Most patients are content with the results of surgery, more often after 
laparoscopic (92%) than after open surgery (76%) [172]. Antireflux surgery can also 
effectively heal esophagitis [33] and may lead to complete regression of BE and to the 
regression of LGD to IM [173]. In one meta-analysis, fundoplication appeared to result in 
better control of the reflux symptoms and in better patient-perceived GERD-related 
quality of life (QOL) than did antireflux medication, although many patients still used 
medication after surgery [174] . Although symptoms and medication use after antireflux 
surgery are important for the aspects of QOL and cost effectiveness, pathologic 
postoperative esophageal acid exposure is detectable in only a minority of patients with 
symptoms or ongoing medication [175, 176]. The postoperative use of PPIs varies greatly 
(15-80%) [177] and increases during the years after surgery, from 2.2% at one year to 
46.5% at the 15-year follow-up [172, 178]). Postoperative PPI use often occurs without 
endoscopically or pH-monitoring-proven findings of reflux [172, 175].  
Preoperative endoscopic findings of GERD, including BE and ERD vs. NERD, do 
not affect the symptomatic outcome of antireflux surgery [70]. In terms of extraesophageal 
symptoms, most studies report a positive response in over 50%, and up to 100%, of 
patients. Of patients with laryngeal symptoms, 65-94% benefit from fundoplication [179]. 
In a study of patients undergoing fundoplication after PPI treatment, fundoplication 
reduced both the esophageal and extraesophageal symptoms more effectively than did PPI 
[61]. Fundoplication may be more effective than medical treatment also in the healing of 
esophagitis [180].  
Operative complications of fundoplication include esophageal or gastric injury, 
pneumothorax, splenic or liver injuries, and postoperative ileus [157]. Postoperative 
symptoms related to fundoplication include dysphagia, inability to belch or to vomit, and 
increased flatulence. Dysphagia and increased flatulence are more common complaints 
after fundoplication than occur on PPI therapy [61]. The long-term durability of surgery is 
not always good. Partial or total plication disruptions have been detectable in 11.1% of 
patients and hiatal hernias in 30.6% at the 15-year follow-up after laparoscopic Nissen 
fundoplication, with significantly higher plication disruption rates after open Nissen 
fundoplication than after laparoscopic fundoplication [172]. Reoperation after 
laparoscopic antireflux surgery has been necessary in 9.6% over a mean follow-up of 7.6 
years [181]. 
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2.11.4 Effect of GERD treatment on EAC development 
The role of GERD as a risk factor for EAC suggests that eliminating this risk factor would 
also diminish EAC incidence. To date, no convincing evidence supports this hypothesis.  
 
2.11.4.1 Antireflux medication 
In addition to acid suppression, PPIs may have additional features such as anti-oxidant and 
immunomodulatory capabilities, and inhibitory effects on the adhesion of malignant cells 
[156]. Cancer-promoting effects of PPIs, resulting from the rise in serum gastrin levels 
and the ability of deconjugated bile salts to cause esophageal damage in a less acidic 
environment, have also been proposed [182]. Further, despite symptom relief, pathologic 
acid reflux is common during PPI therapy [183, 184]. Moreover, during PPI therapy, a 
common problem is non-compliance, manifested as irregular medication usage. No 
conclusive evidence shows PPIs as reducing risk for EAC in patients with BE. A meta-
analysis of observational studies did show a 71% reduction in EAC/HGD risk in BE 
patients with PPI usage, and a pronounced effect with prolonged use. Use of HR2As, as 
analyzed by two of the studies, showed no protective effect [35]. A nationwide, registry-
based study with almost 10 000 patients and a median follow-up of 10 years showed no 
protective effect of PPIs in BE patients; instead, it showed the highest EAC risk in the 
long-term, highly adherent users [34]. To add controversy, a recent large retrospective 
study of BE patients observed a protective effect of GERD treatment (mainly PPIs) on the 
progression to LGD, HGD, or EAC. [185] The severity of GERD symptoms, especially in 
patients using PPI, has been inversely correlated with the risk of patients presenting with 
either BE or EAC, although symptom severity correlated with the presence of esophagitis 
[186]. Interestingly, preoperative PPI usage may indicate a survival advantage in 
surgically treated EAC [89]. 
2.11.4.2 Antireflux surgery 
Antireflux surgery may offer more complete reflux inhibition than does medical treatment, 
because surgery mechanically also prevents duodenogastroesophageal reflux (bile reflux). 
Despite this theoretical advantage, antireflux surgery has not been superior to non-surgical 
treatment of GERD in the prevention of EAC [38-40], and neither does EAC risk decrease 
after antireflux surgery [40, 154].  
In BE patients, antireflux surgery was more efficient than medical treatment in 
inducing the regression of BE or dysplasia in one systematic review [187]. A study 
published after that review suggests a benefit in terms of IM reversal in short-segment BE 
for antireflux surgery over medical therapy, whereas neither therapy modality affects long-
segment BE [188]. The systematic review also found a lower incidence of EAC in 
surgically than in medically treated patients, although in controlled studies this risk was 
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not statistically significant [187]. A previous meta-analysis found no significant difference 
in EAC incidence between the two treatment methods [189]. 
The main factor proposed to contribute to the development of EAC after antireflux 
surgery is persistent postoperative reflux due to failed antireflux surgery. The prevalence 
of abnormal postoperative acid reflux has ranged from 15% to 41% [173, 190]. At a 
median follow-up of 8.9 years after antireflux surgery in BE patients, progression to HGD 
or EAC was more frequent in patients with a disrupted fundoplication (27%)–one 
diagnosed at endoscopy–than in those with an intact fundoplication (3%). The progression 
rate from BE to HGD or EAC was 2.6% per patient year in those with a disrupted 
fundoplication compared to 0.36% in those with an intact plication [191]. Another study 
showed no differences in the clinical, endoscopic, pH-monitoring, or manometric findings, 
or in bilirubin monitoring (by Bilitec™monitor) between BE patients with dysplastic 
progression and those without progression but requiring treatment for recurrent symptoms 
[192]. In one study with a small number of patients, the use of antireflux medication–
interpreted as a sign of persistent reflux–was associated with EAC after antireflux surgery 
[193]. A nested, population-based case-control study has also suggested that patients who 
develop EAC after antireflux surgery exhibit reflux symptoms requiring treatment more 
often than those who do not. BMI, smoking, or type of fundoplication did not affect EAC 
risk [194]. 
2.12 Endoscopic treatment of BE with or without dysplasia 
2.12.1 Endoscopic resection 
Endoscopic resection (ER) serves to remove dysplastic lesions in BE and intramucosal 
EAC (Figure 3 a, b). Endoscopic resections consist of endoscopic mucosal resection 
(EMR) and endoscopic submucosal dissection (ESD). Removal of visible lesions is 
important, since pretreatment biopsies predict final histology at an accuracy of only 61% 
[137]. 
Several techniques for EMR include single-band EMR, multiband mucosectomy 
and cap-assisted EMR. The esophageal mucosa is lifted with suction and resected by 
cauterization. Some techniques require a prior submucosal injection of liquid. In ESD, the 
tissue piece is resected by a special electrocauterized knife to enable an en-bloc resection 
after submucosal liquid injection [195].   
The complications of endoscopic resection techniques include bleeding, 
perforation, and strictures. Some studies report higher perforation and stricture formation 
rates for ESD than for EMR [195]. Currently, ESD is reserved for larger lesions, 
multifocal dysplasia or neoplasia, poorly lifting lesions, and lesions at higher risk for 
submucosal infiltration [195, 196]. The complication rate of endoscopic resection is lower 
than that of surgery [195]. High rates of remission (> 80-90%) have been reported, but 
recurrence has also been at 6% to 30% [195, 197]. 
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(a)                                                            (b) 
 
 
(c)                                                            (d) 
Figure 3 An intramucosal EAC in BE (a) has been resected endoscopically (b). BE has been 
treated with RFA (c). Post-treatment, neosquamous esophageal mucosa (d). 
Reproduced and modified with permission from Massachusetts Medical Society, from 
Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 371: 2499-2509, 
2014. 
2.12.2 Ablation 
Endoscopic ablation techniques comprise thermal ablation techniques including 
radiofrequency ablation (RFA) (Figure 3 c) and argon plasma coagulation, and 
cryotherapy and photodynamic therapy (PDT) [197], with RFA the most common method. 
Due to the low cancer risk in BE, the fairly common BE recurrence after ablation, and the 
costs and side-effects of ablation, this method is currently reserved for dysplastic BE. In 
one cost-effectiveness analysis, RFA seemed cost-effective for LGD, but not for non-
dysplastic BE [198]. The complications of RFA include strictures (5%), pain (3%), 
bleeding (1%), and perforation [199].  
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Ablation aims to replace BE with neosquamous epithelium (Figure 3 d). This 
neosquamous epithelium is like the normal esophageal squamous epithelium, with 
regenerative changes evident especially shortly after ablation [200]. After successful RFA 
for neoplastic BE, the expression of Ki-67 (a proliferation marker) and p53 were 
normalized, and chromosomal abnormalities were undetectable in the neosquamous 
mucosa [201]. The neosquamous mucosa also contains mostly wild-type p16 and p53 
genes, in contrast to adjacent BE [202]. The residual BE, however, shows persistent 
changes, such as increased Ki-67 expression and increased COX-2 and p53 expression 
[203, 204]. The origin of cells giving rise to the neosquamous epithelium–a reverse event 
in the development of BE–is unclear [200].  
Effective reflux control, either medical or surgical, should be combined with 
endoscopic treatment of BE to lower the risk for recurrence. Recurrent intestinal 
metaplasia or dysplasia is most commonly found near the gastoesophageal junction and is 
macroscopically invisible in 40% [30]. Invisible IM at the new SCJ has been detected in 
24% of patients during follow-up, most often without confirmation in the next 
endoscopies, however [31]. Risk for EAC persists even after successful ablation. EAC 
may arise from either residual or recurrent intestinal metaplasia, or from buried 
subquamous glandular tissue. Recurrent dysplasia or EAC can often be treated 
endoscopically [31, 205, 206], yet a significant number of EACs also progress to invasive 
disease that may be locally advanced or metastatic [207].  
2.12.2.1 Efficacy of ablation 
Studies exploring the efficacy of ablation methods are heterogenic in their patient material 
(variable proportions of patients with BE, dysplasia, and neoplasia), and the methods used 
(ablation methods, proportions of patients with ER). Moreover, determination of stage 
(HGD, intramucosal carcinoma = IMC, EAC) varies, and endpoints differ. Most studies 
since 2007 deal with the currently preferred RFA method [208], which has proven 
superior to a sham procedure or surveillance in preventing disease progression in 
dysplastic BE [32, 209]. 
In patients with BE, with or without dysplasia or neoplasia, initial eradication of 
intestinal metaplasia has been successful in 77% to 87%. Eradication of dysplasia or 
neoplasia of variable degrees has been successful in 86% to 92% of patients after RFA and 
possible associated EMR for focal lesions [31, 199, 209]. The results of RFA with or 
without EMR have improved over time, with an increasing rate of associated EMR 
procedures performed on focal lesions [207]. Long BE and long duration of dysplasia 
predispose to incomplete response (residual metaplasia or dysplasia) after four to five 
RFA treatments [197]. 
 Most studies on BE ablation (with or without EMR) have reported follow-up of 
only 2 to 3 years. Recurrence rates have been 8% to 11% for recurrent IM and 4% to 5% 
for a neoplastic recurrence, but with recurrence rates sometimes as high as 33% by 2 years 
[30, 31, 205]. The longest follow-up available today after RFA with a prior endoscopic 
resection in 72% for BE with high-grade intraepithelial neoplasia or early-stage cancer, or 
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both, showed excellent results at the 5-year surveillance, with 90% in remission for both 
IM and neoplasia [210]. In contrast, a study with ablation or endocopic resection (in a total 
of 81%), or both, for HGD and IMC patients found that at the 5-year follow-up, only 20% 
were in remission for both IM and dysplasia or neoplasia [206]. 
2.12.2.2 EAC risk after ablation 
The rate of progression to EAC after RFA has been 0.78% annually, with mostly lower 
progression rates for BE, LGD, and HGD than reported for patients without ablation 
[211]. In other studies, the rate of patients progressing to EAC after ablation (varying 
histologic grades, with or without EMR) at the 1- to 1.5-year follow-up has been 0.7% to 
3.6% [199, 207, 209]. However, a significant proportion (6.7%) have progressed to 
invasive EAC later (at a median 2.6 years) [207]. The significance of entry histology at 
ablation for the eradication results has been uncertain. Some studies have found that 
pretreatment histology may impact on both the efficacy of achieving complete eradication 
of BE with or without associated dysplasia or neoplasia and on the durability of the 
eradication, with worse results at more advanced stages [199, 212]. Other studies have not 
confirmed this significance for effect of pretreatment histology [205, 206, 213]. In a recent 
multicenter study, higher pathologic grade of BE and the longer length of BE, in addition 
to subsquamous pathology, predicted EAC development [211]. Annual EAC incidence 
after ablation was 3.0% in HGD, 0.43% in LGD, 0.15% in long-segment BE, and 0% in 
short-segment BE in that study of 4 698 patients. Higher entry pathology predicted 
mortality, and also that of EAC, which was 0.07 % annually. In the same study, of the 
post-ablation EAC cases, 46% were invasive, and 54% were intra-mucosal at detection, 
and intestinal metaplasia had been successfully eradicated earlier in only 15% and 27% of 
these patients [211].   
Another study showed that in patients with HGD or IMC, the recurrence rate for 
dysplasia or neoplasia did not differ between those who achieved complete eradication of 
IM and those who did not [206].  Possible explanations for these differing results are 
varying treatment protocols in terms of technique, follow-up, and histopathologic 
examination, and the relatively small number of patients in each category. Frequent 
endoscopic surveillance, starting with 3- to 6-month intervals depending on pretreatment 
histology, and subsequently annually, is recommended after IM eradication [129]. 
2.12.2.3 Intestinal metaplasia buried under squamous epithelium 
Intestinal metaplasia persisting underneath the neosquamous epithelium is a potential 
source for malignant development. This buried subsquamous IM occurs in BE also 
without ablation [209]. Buried BE is similar to non-buried BE, with a surface connection 
observed in 68% [200]. The frequency of post-ablation buried IM or dysplasia varies 
across studies and depends on treatment method. Sufficiently deep biopsies are needed to 
detect it. In one systematic review, buried subsquamous metaplasia was detectable in 0% 
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to 28% of patients before ablation, in 0.9% after RFA, and in 14.2% after PDT, and this 
buried metaplasia often occurred at the border of squamous and columnar epithelium 
[214]. In one sham-controlled trial, the prevalence of subsquamous intestinal metaplasia 
was lower after RFA (5% at 1 year) than before RFA (25%) in patients with dysplastic BE 
[209]. In recent studies, buried glands have been detectable in 0.02% to 0.08% of all the 
biopsies after RFA with or without endoscopic resection [31, 210].  
EAC and HGD arising in the subsquamous buried glands after ablation have been 
detected [205, 214, 215], but the rate of progression of subsquamous IM has been 
unknown [10]. In a recent study, subsquamous BE (with or without dysplasia or neoplasia) 
before ablation predicted development of EAC, which developed at a rate of 5.0% 
annually. Subsquamous BE appeared in 3% of patients before IM was eradicated: 69% of 
the cases nondysplastic, and 5% representing EAC, and in only 0.8% after successful 
ablation and with no EAC detectable at that point [211]. In patients with mostly neoplastic 
BE, subsquamous IM has appeared in EMR resection samples of 98% patients, with 60% 
of the samples exhibiting a neoplastic subsquamous component [216]. After ablation with 
RFA or PDT for HGD or IMC, subsquamous HGD or neoplasia occurred in 2%, although 
benign subsquamous glands occurred only rarely [217]. One speculation is that decreased 
acid exposure to the cells hidden underneath the squamous epithelium may protect them. 
On the other hand, blockage of the glandular secretion might induce malignant 
development [200]. Buried BE has lower proliferation (Ki-67 expression) than does the 
adjacent BE [218], and after PDT, shows lower proliferation (Ki-67) than before 
treatment, and a normal DNA-content profile [203].  
2.13 Molecular biology of GERD, BE, and EAC 
2.13.1 Biomarkers 
Various molecules that participate in carcinogenetic pathways have shown alterations 
during the development of EAC without any determining mechanism yet discovered. The 
goal in characterizing molecular expression is to gain means for prevention, treatment, and 
prognosis, and especially to find molecules to guide treatment of the various stages of 
GERD or EAC. These biomarkers are classified as 1) diagnostic of a condition (BE / 
EAC), 2) as indicating progression (of BE to malignancy), 3) as predictive of a response to 
therapy, and 4) as prognostic markers [18, 219]. Various molecules and genetic 
abnormalities appear in each category, but no single biomarker or a panel of them has yet 
proven useful for clinical decision-making. Based on the current marker panels, the nature 
of BE as being molecularly similar to GERD or EAC, or as a stage with distinctly 
individual molecular expression is controversial. The various alterations may occur at 
genetic level, in epigenetic regulation, or in expression of mRNA or of mature proteins. 
Potential serum biomarkers have also been evaluated, among them, antibodies to p53 [17].  
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Genome-wide association studies have found several loci associated with both BE 
and EAC [102, 220, 221]. DNA-content abnormalities at specific loci (including those of 
p53 [222]) and more generally (aneuploidy, tetraploidy) both predict EAC, with an 
enhanced effect for a combination of markers [113]. At epigenetic level, a genome-wide 
methylation analysis found the methylation patterns between the normal esophagus and 
BE or EAC to differ, while the distinction between BE and EAC was less clear [223]. 
Several microRNAs also show changes in BE and EAC, and have been identified as 
potential biomarkers. They seem not, however, to aid in distinguishing HDG or EAC from 
BE [224]. Clonal diversity – mostly genetic - predicts the progression of BE to EAC [225, 
226], with the main determinant being diversity rather than any specific alteration [225]. 
Mature proteins with potential biomarker value include cell-cycle predictors 
(cyclin D1 both in the progression to EAC and in the prognosis of EAC), proliferation 
markers (Ki-67 in prognosis of EAC), tumor suppressors (p53), caudal homeobox 
transcription factor-2 (Cdx2) for BE, receptor tyrosine kinases, mucins, and stem cell 
markers [17, 219]. Aberrant p53 expression elevates the risk for progression of BE to 
EAC, with a higher risk from loss than from gain of its expression, and may be an even 
stronger predictor of progression than is low-grade dysplasia [23]. Mutated p53 also has a 
negative impact on prognosis in curatively resected Barrett’s adenocarcinoma [227]. 
Additionally, p53 has been suggested as a marker for the prediction of response to 
chemotherapy [18, 219]. One gene expression analysis found differring sets of genes to be 
expressed in the normal esophagus, in BE, and in EAC, with EAC showing 
downregulation of many genes associated with epidermal differentiation [228]. In contrast, 
another gene expression study found a significant similarity between BE and EAC when 
compared to normal esophagus [229]. 
2.13.2 Caudal-related homeobox gene 2 (Cdx2) 
Embryologic signaling pathways are implicated in the pathogenesis of BE [230-232]. 
Cdx2 is a transcription factor expressed during intestinal development in mice and a 
contributor to intestinal differentiation [233, 234].  
Cdx2 expression has been increased by bile acids in esophageal adenocarcinoma 
and squamous cell lines [232], an effect enhanced by acidification in the Barrett’s 
adenocarcinoma cell line (OE-33) [235]. In esophageal squamous cells, acid and bile salts 
lead to increased Cdx2 expression in cell lines from patients with BE but not in those 
without BE [236]. In one transgenic mouse model, Cdx2 expression in the squamous 
epithelium led to a transitional cell type between squamous and BE cells, with a weakened 
epithelial barrier [237]. Cdx2 mRNA may be found in esophageal squamous mucosa, 
mostly in BE patients [238, 239]. Cdx2 protein is expressed in 100% of BE samples, and 
only partly expressed (30%) in non-intestinalized esophageal columnar epithelium [240]. 
Cdx2 mRNA- and protein expression is elevated in BE and Barrett’s adenocarcinoma 
relative to that in squamous epithelium. The Cdx2 protein expression is nuclear [241].  
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2.13.3 Inflammation and oxidative stress 
Inflammation is implicated in the development of many cancers. Inflammatory pathways 
are part of the signaling networks of the tumor microenvironment [242], even in cancers 
not causally related to an inflammatory condition [243]. In fact, Hanahan and Weinberg 
have classified tumor-promoting inflammation as a factor enabling the acquisition of the 
hallmarks of cancers, along with genome instability and mutation [244]. The inflammation 
may derive from an existing inflammatory condition or from genetic events occurring in 
the neoplastic process [243]. In GERD, gastric and bile acids cause mucosal damage and 
inflammation, which may lead to the production of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), both of which cause DNA damage and genetic or 
epigenetic changes that in turn may lead to the activation of the intrinsic inflammatory 
pathway [245]. The relative contribution of extrinsic or intrinsic inflammation in the 
development of EAC is unclear. Two important cancer-promoting inflammatory 
pathways: the nuclear factor-κB (NF-κB) pathway and the interleukin 6 / signal transducer 
and activator of transcription 3 pathway, each seem to play a role in Barrett’s 
carcinogenesis [245].  
Inflammation activates the immune system, which also plays a role in tumor 
suppression. The ability of a tumor to avoid destruction by the immune system may in fact 
be an additional hallmark of cancer [244]. The immune responses–the type of cytokines, 
and the type of T-cells in the squamous epithelium–between reflux esophagitis and BE 
differ [246, 247]. In reflux esophagitis, esophageal mucosa expresses proinflammatory 
and T helper-1 type cytokines, whereas in BE it expresses T helper-2 type cytokines [246]. 
The tumor microenvironment of EAC may be dominated by immunosuppressive 
molecules [248]. 
Oxidative stress, ROS and RNS, also may contribute to the acquisition of all the 
capabilities essential for tumor development reported by Hanahan and Weinberg: self-
sufficiency in growth signals, insensitivity to anti-growth signals, limitless replicative 
potential, avoidance of apoptosis, sustained angiogenesis, tissue invasion, and metastatic 
potential [249, 250]. Markers of oxidative stress studied in GERD, BE, and EAC include 
8-hydroxydeoxyguanosine (8-OhdG), a marker of oxidative DNA damage; DNA-adducts; 
myeloperoxidase (MP), a peroxidase enzyme produced by inflammatory cells; superoxide 
dismutase (SOD) that turns the superoxide radical into oxygen and hydrogen peroxide; 
and glutathione (GSH), a redox buffer balancing the actions of ROS. Oxidative stress has 
been increased in BE and in associated dysplasia or neoplasia, appearing as increased 8-
OhdG and MP levels and as increased DNA-adducts [251-254]. Most often, no 
progressive trend in oxidative stress has been found in the metaplasia–dysplasia–EAC 
sequence [251, 252, 255], although some results suggest otherwise [253]. Findings 
concerning antioxidant GSH content and SOD activity are conflicting. GSH content has 
been diminished in all stages of GERD to EAC, but in esophagitis, increased levels have 
also occurred [252, 254, 256]. Whereas the expression of SOD in GERD seems increased, 
its activity has been reduced, unchanged, or increased in esophagitis and BE, and 
increased in dysplastic BE [252, 254-256]. After antireflux surgery, both the oxidative 
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stress and antioxidant capacity in the esophageal mucosa have decreased (the levels of MP 
and GSH decreased), but not normalized, even 4 years postoperatively [257].  
 
2.13.4 ADAMs 
A disintegrin and metalloproteinases, ADAMs, are molecules belonging to the metzincin 
superfamily of proteases that participate in many signaling activities [20]. In addition to 
the metalloproteinase domain responsible for their proteolytic activity, ADAMs possess 
various domains that extend their capabilities, entailing a disintegrin domain with a 
possibility to interact with integrins, a cystein-rich domain for cellular adhesion, an EGF-
like domain, a transmembrane domain, a cytoplasmic tail (containing regulatory 
phosphorylation and SRC 3 homology domain-binding domains), and a prodomain the 
removal of which activates the metalloproteinase domain [258].  
ADAMs are able to cleave many signaling molecules involved in cancer, including 
tumor necrosis factor alpha and transforming growth factor beta, as well as cellular 
adhesion molecules (E-cadherin, CD44) [20, 259, 260], all of which have been implicated 
in EAC, or in the malignant progression of BE [261-263]. Studied in cell lines, ADAM9 
expression has been promoted by oxidative stress, which may also contribute to the 
invasive potential of neoplastic cells [264, 265]. ADAM-integrin interaction may play a 
role in this cellular invasion [265].  Increased expression of ADAMs has emerged in many 
human cancers at mRNA- or protein level [20], including many adenocarcinomas, like 
gastric or breast cancer [21, 266, 267]. ADAM-protein expression in cancer has been 
localized in the cytoplasm and the cell surface [21, 266]. In EAC, many ADAMs have 
shown increased expression at mRNA level, with no information on this at protein level or 
in GERD or BE, however. The mRNA levels of ADAMs 9, 10, 12, 17, and 19 were 
approximately 1.6- to 3.8-fold increased in cancer compared to adjacent normal tissue, 
with the highest increase for ADAM12 [22]. ADAMs 12 and 19 have been increasingly 
hypermethylated both in BE and in EAC [223], suggesting their suppressed expression. 
Expression of ADAMs has been associated with prognosis in many cancers. In gastric 
cancer, ADAM10 expression is associated with more advanced disease, and with poorer 
survival in stages I to III [268]. High ADAM9 expression is associated with shorter 
survival in curatively resected stage I non-small cell lung cancer [269]. Similarly, high 
ADAM17 expression is associated with shorter survival in breast cancer [270]. 
Observations of the role of ADAM expression in cancer have led to investigations of the 
usefulness of anti-ADAM medication [46]. One inhibitor of ADAM17 has been shown to 
reduce proliferation in breast cancer cell lines and to sensitize them to chemotherapeutic 
agents [271]. 
Many of the molecules shed by ADAMs participate also in inflammatory processes 
[19]. In Helicobacter pylori-infected gastric mucosa and in gastric cancer, expression of 
ADAM 10 and 17 mRNA has been increased [267]. In epithelial-mesenchymal transition, 
a key process in the ability of a tumor to invade, an important event is the loss of E-
cadherin. Patients with NERD or ERD have increased junctional permeability along with 
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cleavage of E-cadherin in their distal esophagus, and ADAM10 seems to play a role in in 
that cleavage [272].  
2.13.5 c-MYC and CIP2A 
c-MYC is an oncogenic transcription factor that can either induce or repress gene 
expression, with any changes resulting from its overexpression depending on cell type 
[273]. c-MYC participates in cellular processes such as apoptosis, differentiation, and 
proliferation. It is increased in many cancers such as gastric cancer and colonic 
adenocarcinoma [273]. It is also overexpressed in 73% to 90% of EAC cases, and in 37% 
to 50% of BE cases [274, 275]. Its expression rises in a linear fashion from controls to BE, 
BE with dysplasia, and EAC [274]. In BE, c-MYC is expressed in the nucleus, but with 
BE progression cytoplasmic staining increases. Due to its expression’s being already 
frequent in BE, one suggestion is that in BE progression, other dysregulations–such as 
mutated p53–act synergistically. Bile acids, in an acidic environment, induce c-MYC 
expression in vitro [275]; also in vitro, c-MYC has induced the development of ROS 
[276].  
Closely linked to c-MYC, the cancerous inhibitor of protein phosphatase 2A, 
CIP2A, is an oncogene increased in many human cancers [25]. As its name implies, it 
inhibits the tumor-suppressor protein phosphatase 2A (PP2A). PP2A regulates 
transcription factors such as p53 and c-MYC, and inhibition of its function in 
dephosphorylating c-MYC is one factor required for malignant cellular transformation. 
CIP2A inhibits PP2A by interacting directly with c-MYC and thereby protecting it from 
degradation [24]. c-MYC and CIP2A promote each other’s expression in a positive 
feedback loop [277]. CIP2A promotes cellular growth and transformation, and promotes 
tumor growth (in mice) [24], and also acts independently of PPA2 in processes such as 
mitosis and cell-cycle progression. Its depletion leads to impairment in mitosis and delay 
in cell division [278].   
CIP2A expression is increased in various cancers, including gastric, colorectal, and 
esophageal squamous cell carcinoma [24, 26-28]. CIP2A positivity has appeared in 90% 
of gastric cancer and of esophageal squamous cell carcinoma cases, whereas in normal 
tissues, it has appeared in 27% of gastric mucosa and 20% of esophageal mucosa [26, 27]. 
Increased CIP2A protein expression is mainly cytoplasmic in gastric and in colon cancer 
[26, 28]. In cancer cell lines, CIP2A depletion leads to impaired growth and clone 
formation, and to cellular senescence [26, 27]. In gastric cancer (with tumors ≤ 5 cm), 
CIP2A expression has been associated with reduced survival [277]. In other cancers as 
well, such as liver, colon, and pancreatic cancer, CIP2A plays a role as a prognostic factor 
[25]. CIP2A expression may also predict response to various antitumor agents. Targeting 
CIP2A instead of MYC in cancer treatment might be beneficial, since MYC function is 
essential for normal cells, but that of CIP2A does not seem to be [24, 25]. The 
overexpression of CIP2A is associated with both the expression of nuclear c-MYC and 
with p53 in colorectal cancer [28]. In breast cancer, CIP2A mRNA expression is 
associated with p53 mutation [279].  
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3 Aims of the study 
1. A distegrin and metalloproteinases, ADAMs, are implicated in both inflammatory 
processes and cancer. They have been preliminarily found to be overexpressed in 
EAC. We aimed to define their expression in the development of EAC through the 
esophagitis–metaplasia–dysplasia–EAC sequence.  
 
2. CIP2A is an oncogene overexpressed in many cancers. Its expression has often had 
a prognostic impact. We aimed to investigate its expression in EAC, together with 
the interacting oncogene c-MYC, and also the possible influence of both on EAC 
prognosis.  
 
3. The effectiveness of BE ablation and the properties of the neosquamous mucosa 
have been unknown at long-term follow-up. We aimed to assess the long-term 
effects of laser ablation of BE, combined with antireflux surgery, on the recurrence 
of BE, on oxidative stress, and on the malignant potential of the neosquamous 
mucosa. 
 
4. The incidence of EAC after antireflux surgery at population level has been 
unknown, and we aimed to define this incidence at a 20-year interval in Finland. 
The factors causing EAC to occur after antireflux surgery are disputable, so we 
explored factors that might predispose to EAC after antireflux surgery, such as 
anatomic and functional failure of antireflux surgery.  
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4 Patients, materials, and methods 
4.1 Patients and materials 
Study I 
 
Esophageal biopsies were collected from patients presenting for a diagnostic or 
therapeutic upper gastrointestinal endoscopy or esophageal surgery in Helsinki University 
Hospital during 2007 - 2010. Samples were collected at the different stages of GERD: 
esophagitis (mild in 11, severe in 5), BE (20 patients), BE with low-grade dysplasia (5) 
and with high-grade dysplasia (7), and EAC (20). Patients with normal histological 
esophageal mucosa  (26) served as controls. Of the EAC cases, 7 (35%) were Siewert I 
tumors, and 13 (65%) were Siewert II, and 5 (25%) patients had received neoadjuvant 
treatment. Differentiation of EAC cases was quite uniformly distributed between good 
(30%), moderate (35%), and poor (35%). Preliminary analysis of the expression of a 
disintegrin and metalloproteinases (ADAMs) was conducted with cell lines of a Barrett’s 
adenocarcinoma (OE33) and of an adenocarcinoma of the gastroesophageal junction 
(OE19). We used the cell line Het-1A (from normal esophageal tissue, and transfected 
with a Simian Virus 40 large T antigen) as a control cell line. 
 
Study II 
 
This study included EAC patients from Tampere University Hospital in 1990-2007 and 
those surgically treated for EAC at Helsinki University Hospital during the same years, 
and with available tissue material, totaling 127. Of these patients, 72 (57%) had undergone 
surgical treatment for their cancers. 97.6% had cancer in either the distal esophagus or in 
the esophagogastric junction. Samples also included numbered 5 from the squamous tissue 
near the tumor, and 33 from BE from the cancer patients.  
 
Study III 
 
Patients comprised those 18 treated with neodymium-yttrium-aluminum-garnet (Nd-YAG) 
laser ablation of Barrett’s esophagus and antireflux surgery for GERD at Helsinki 
University Central Hospital during 1992-2005 and available for follow-up by upper 
gastrointestinal endoscopy. One additional patient diagnosed with gastric cardia 
adenocarcinoma (distal from fundoplication) 4.3 years after ablation had been excluded. 
Sixteen patients had undergone a complete fundoplication (three laparoscopic, one 
combination of laparoscopy and minilaparotomy), one had open partial posterior 
fundoplication, and one underwent partial gastrectomy with Roux-en-Y reconstruction 
with vagotomy and fundophrenicopexy. Esophageal pH-monitoring was normal in all the 
17 patients who underwent it. The average BE length before ablation was 3.6 cm (range 
0.5–6 cm). Controls for the oxidative stress analysis were patients without GERD 
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symptoms or esophageal pathology at endoscopy (numbering 14 or 9 depending on the 
substance measured).  
 
Study IV 
 
The Finnish Cancer Registry provided information on all the 1035 patients with a 
diagnosis of esophageal adenocarcinoma during 1980-2006 in Finland. From the National 
Institute for Health and Welfare (THL), records covered the 19 542 patients who 
underwent antireflux surgery during 1987-2006 (registry data available since 1987). 
Patient records of all EAC patients allowed identification of all those with a previous 
antireflux surgery. Their patient records were ordered from the hospitals that had provided 
the information for the Cancer Registry, and death certificates of those with insufficient 
information came from Statistics Finland. Final analysis was conducted on 53 EAC 
patients with prior antireflux surgery. Analysis of the standardized incidence ratio of EAC 
after antireflux surgery involved the antireflux surgery patients of 1987-2006 and an age-, 
sex- and calendar-period-matched Finnish population.  
4.2 Methods 
4.2.1 Acquisition of clinical data 
In Study I, basic data were collected on the patient characteristics and tumor location as 
well as on neoadjuvant treatment. 
 
In Study II, data were collected on the type and location of the tumor, the treatment and 
the disease state of the patients.  
 
For Study III, the macroscopic state of the esophageal mucosa and the state of the 
fundoplication were assessed during an upper gastrointestinal endoscopy. Data on the 
antireflux surgery and laser treatment came from patient records.  
 
In Study IV, records were thoroughly surveyed of all patients with a previous antireflux 
surgery. Data were collected on the patients’ history of GERD  (such as BE, hiatal hernia, 
esophagitis) before and after antireflux surgery, on smoking or alcohol use, medications 
affecting GERD, type and time of antireflux surgery and the outcome of antireflux surgery 
in follow-up, and the diagnosis of EAC. 
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4.2.2 Acquisition of tissue samples 
In Study I, tissue samples were taken from approximately 2 and 15 cm above the 
gastroesophageal junction. For mRNA analysis, the samples were placed in RNAlater 
(Qiagen, Hilden, Germany) and for protein analysis, were either fast-frozen or placed 
directly into formalin.   
 
In Study II, tissue samples were formaldehyde-fixed, paraffin-embedded samples 
collected earlier for diagnostic and therapeutic purposes.  
 
For Study III, biopsy samples were drawn during esophago-gastroscopy from the 
squamous epithelium of the esophagus at 1, 3, and 15 cm above the squamocolumnar 
junction. For the control group, samples were drawn at 5 cm and at 20 cm (for 8-OhdG) 
above that junction. Samples were either fast-frozen (for the oxidative stress analysis) or 
placed in formalin (for immunohistochemistry).  
4.2.3 Histologic analysis 
In Studies I to III an experienced pathologist analyzed the histology.  
4.2.4 Oxidative stress analysis 
Analysis of 8-OHdG, SOD, GSH, and MP levels took place at the MCA Research 
Laboratory Ltd. in Turku, Finland. The techniques have been described previously: 8-
OHdG was measured by high-performance liquid chromatography with an 
electrochemical detector (and a ultra violet-detector for deoxyguanosine) [251]; SOD 
activity was measured by the method of Laihia and colleagues [280]; GSH content was 
measured by Saville’s method [281]; MP activity was measured with Suzuki’s modified 
method [282]. Concentrations are expressed as the ratio of 8-OHdG per 105 dG (8-OHdG), 
units/mg protein (SOD, MP), and nmol/mg protein (GSH).  
4.2.5 mRNA quantification 
In Study I, mRNA was isolated with the RNeasy Mini Kit (Qiagen, Germantown, MD, 
USA) for cell lines, and with the RNeasy Fibrous Tissue Mini Kit (Qiagen) for tissue 
samples that were first homogenized. Reverse transcription was performed with the High 
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) and reverse 
transcription-PCR (RT-PCR) was then performed and cDNA measured with ABI Prism 
7000 Sequence Detection Software with Taqman technology. Primers (ADAM9: 
Hs00177638_m1, ADAM10: Hs00153853_m1, ADAM12: Hs01106104_m1, ADAM17: 
Hs00234224_m1, and ADAM19: Hs00224960_m1) were from Applied Biosystems. The 
 
 
 
 
44 
results were standardized with a dilution batch of the cell line NCI-N87 run in every plate, 
and in cell lines with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression 
and in tissue samples also with beta-actin expression. 
4.2.6 Protein quantification 
In Study I, after extraction of the proteins from the cell lines, the Quant-it kit (Invitrogen, 
Eugene, OR, USA) and a fluorescence plate reader (Wallac 1420, Perkin-Elmer, Turku, 
Finland) served for protein quantification by Western blotting. An Odyssey infrared 
scanner (LI-COR, Lincoln, NE, USA) served for protein detection after incubation with 
primary antibodies at a dilution of 1:1000 (ADAM9: sc-23290, ADAM12: sc-25579, and 
ADAM19: sc-25988 from Santa Cruz Biotechnology, and ADAM10: AB936, and ADAM 
17: MAB9302 from R&D Systems) and secondary antibodies at a dilution of 1:15 000 
(Donkey-anti-goat Alexa Fluor 680, A21084, Invitrogen; Goat-anti- rabbit Alexa Fluor 
680, A21109, Invitrogen; Goat-anti- mouse Alexa Fluor 680, A21058, Invitrogen; IRDye 
800CW Donkey-anti-Rabbit, 926-32213, LI-COR Bioscience; IRDye 800CW Goat-anti- 
Mouse, 926-32210, LI-COR Bioscience; IRDye 800CW Goat-anti-Rabbit, 926-32213, LI-
COR Bioscience). Results were standardized with GAPDH expression. 
For immunohistochemistry (IHC), samples from 6 controls, 3 patients with severe 
esophagitis, 3 with BE, 5 with dysplastic BE, and 7 with esophageal adenocarcinoma were 
selected irrespective of their mRNA expression. After antigen retrieval from the formalin-
fixed, paraffin-embedded samples, and after blocking, the glasses were incubated with 
primary (ADAM9: AB19024, dilution 1:400, Millipore; ADAM10: AB936, 1:750, R&D 
Systems; ADAM12: LS-B2756, 1:2000, LifeSpanBioSciences; ADAM17: HPA010738-
100UL, 1:50, Sigma-Aldrich; and ADAM19: sc25988, 1:200, Santa Cruz Biotechnology) 
and secondary antibodies [ImmPRESS™ Reagent Kit peroxidase, Anti-Goat Ig and 
Universal Anti-Mouse/Rabbit Ig (Vector Laboratories, Burlingame, CA, USA)] and then 
coated. The staining was classified as 0=no staining, 1=mild staining, 2= medium and 
3=strong, and analyzed by two of the researchers. 
 
In Study II, immunohistochemical analysis of CIP2A and c-MYC expression was 
performed by a tissue microarray technique (TMA). Three representative regions chosen 
from surgical samples were sorted into multitissue blocks. Biopsy samples were prepared 
as paraffin blocks. Staining was performed with the Ventana BenchMark Series automated 
slide preparation system (Ventana Medical Systems, Tucson, AZ, USA).  A rabbit 
polyclonal anti-human antibody served to detect CIP2A (1:100, Bethyl Laboratories Inc, 
Montgomery, TX, USA) and a mouse monoclonal antibody for c-MYC (1:150, 
Novocastra, Newcastle, UK). Staining intensity was classified into four categories 
(0=negative, 1=weak, 2=moderate, 3=strong), and staining extensiveness was also 
classified into four categories (0=negative; 1= weak, 0-30%; 2=moderate, 30-60%; 
3=strong, 60-100%). The integration of these scores yielded an overall score used for 
analyses. Staining was scored independently by two researchers, with the highest score of 
the three samples chosen for analysis. 
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In Study III, immunohistochemical staining to detect caudal-related homeobox gene 2 
(Cdx-2) and p53 was performed for 13 patients by Histola Research Ltd (Tampere, 
Finland) with the NCL-p53-DO-7 antibody for p53 (LeicaMicrosystems, Wetzlar, 
Germany) and the Cdx-88 antibody for Cdx-2 (Biogenex, Fremont, CA, USA).  
4.2.7 Statistical analysis 
Statistical analysis was conducted with SPSS software versions 14.0-22.0 (SPSS Inc., 
Chicago, IL, USA). A p-value ≤ 0.05 was considered statistically significant.  
 
In Study I, the Kolmogorov-Smirnov test served for assessing the normality of the data. 
Student’s t-test (paired/unpaired), the Mann-Whitney and Wilcoxon signed-rank tests were 
used accordingly. ANOVA with Dunnett’s test for correction of multiple comparisons, 
and Kruskall-Wallis and Dunn tests for correction of multiple comparisons were also used 
accordingly. The ADAM expression trend during the control–esophagitis–metaplasia–
dysplasia–EAC sequence was analyzed by the Jonckheere-Terpstra test. 
 
Study II statistics comprised the chi-square test, Cox regression survival models, 
multinomial regression models, and the Pearson correlation coefficient.  
 
Study III used Shapiro-Wilk’s test (to assess normality of the data) and the Mann-Whitney 
test.  
 
Study IV used an unpaired t-test for continuous variables and chi-square or Fisher’s exact 
test for categorical variables. The standardized incidence ratio (SIR) was calculated in the 
Finnish Cancer registry.  
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5 Results 
5.1 ADAM expression profile in GERD and in EAC 
5.1.1 ADAM expression in cell lines 
ADAMs 9 and 17 showed increased expression of mRNA in the EAC cell lines 
(ADAM17 in OE33 only) (Figure 4). The mRNA expression of the other ADAMs studied 
was diminished (Figure 4). The mature protein form at 75 kD of ADAM9 was increased in 
OE33 [integrated intensity 14.1, standard error of mean (SEM) 2.4] as compared to Het-
1A (1.3, SEM 0.19), p<0.001, whereas another mature form, observable at 80 kD, was 
decreased both in OE33 (integrated intensity 0.49, SEM 0.22 vs. Het-1A 2.6, SEM 0.44, 
p=0.0031) and in OE19 (integrated intensity 0.18, SEM 0.15 vs. Het-1A 2.6, SEM 0.44, 
p=0.0026). For ADAM10, both the precursor form at 80 kD and the mature protein form 
at 60 kD were increased in OE33 (integrated intensity for the precursor form 0.65, SEM 
0.11 vs. Het-1A 0.073, SEM 0.027, p=0.0011; and for the mature form 0.36, SEM 0.11 vs. 
Het-1A 0.0041, SEM 0.0075, p<0.001), and in OE19 (integrated intensity for the 
precursor form 0.26, SEM 0.047 vs. Het-1A 0.073, SEM 0.027, p=0.0095; and for the 
mature form 0.26, SEM 0.012 vs. Het-1A 0.0041, SEM 0.0075, p<0.001). For the other 
ADAMs, no changes were detectable in their protein expression (ADAM12: a precursor 
form detected, ADAM17: a precursor and a mature form detected, ADAM19: small 
fragments detected). 
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Figure 4 ADAM mRNA expression in esophageal cell lines. Expression is reported as relative 
to that in Het-1A (expression = 1), and corrected with GAPDH-expression. * p ≤0.05 
between the EAC lines and Het-1A. Error bars indicate standard error of the mean. 
AC = adenocarcinoma, OE33= cell line of Barrett’s adenocarcinoma, OE19 = cell 
line of adenocarcinoma of the gastroesophageal junction. Reproduced and modified 
from Kauttu T, Mustonen H, Vainionpää S, Krogerus L, Ilonen I, Räsänen J, Salo J, 
Puolakkainen P. Disintegrin and metalloproteinases (ADAMs) expression in 
gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin Transl 
Oncol. 19:58-66, 2017. With permission of Springer. 
5.1.2 ADAM expression in human samples 
ADAM mRNA expression varied in different stages of GERD as shown in Figure 5. All 
the ADAMs studied exhibited differential mRNA expression across groups (ADAM9 
p=0.002, ADAM10 p=0.007, ADAM12 p<0.001, ADAM17 p=0.001, ADAM19 p=0.002).  
For ADAMs 9, 12, and 19, a rising trend emerged in their mRNA expression during the 
progressive stages of GERD (ADAM9 p=0.001, ADAM 12 p<0.001, ADAM19 p<0.001). 
Neither ADAM10 nor ADAM17 mRNA showed such a trend.  
In the subgroup analyses, distal ADAM mRNA expression in severe esophagitis 
was increased in comparison to mild esophagatis for ADAM12 (median 281.0, range 29.8-
3302.3 vs. median 14.6, range 5.2-67.6; p=0.010) ADAM17 (median 0.9, range 0.8-1.4 vs. 
median 0.8, range 0.3-1.4; p=0.014) and ADAM19 (median 5.9, range 3.5-32.3 vs. median 
1.6, range 0.5-6.2; p=0.006). ADAM9 was increased in Siewert 1 tumors in comparison to 
Siewert 2 tumors (median 3.0, range 1.8-5.9 vs. median 1.6, range 0.8-4.2; p=0.036). 
Neither neoadjuvant treatment, nor cancer differentiation, nor dysplasia grade had any 
impact on ADAM expression (data not shown).  
In the protein expression analysis by immunohistochemistry, for normal 
squamous epithelium, only ADAM19 showed mild-moderate cytoplasmic expression and, 
rarely, ADAM12 was localized to cytoplasmic granules centered apically. ADAMs 9, 10, 
or 17 were not distinctly expressed. In the glandular tissues, ADAM expression was more 
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often evident. Expression was mostly cytoplasmic; nuclear expression was also detectable 
in some EAC samples.  
ADAM9 protein was increased in EAC relative to that in controls (median 1, 
range 1–2 in EAC vs. median 0.5, range 0–1, p=0.026), but in BE or dysplastic BE, its 
expression did not differ from controls’. ADAM10 protein was also increased in EAC  
(median 2, range 1–2 in EAC vs. median 1, range 0–1 in controls, p=0.021), but no 
statistically significant increase was detectable for BE or dysplastic BE. Dysplastic BE 
showed more uniform ADAM10 distribution than did BE, with a predisposition for basal 
ADAM10 expression. ADAM12 protein was not differently expressed between patients 
and controls. ADAM17 protein was increased in BE (median 2, range 2–2 vs. median 0.5, 
range 0–1 in controls, p=0.024). ADAM19 protein was not differently expressed between 
patients and controls, although it was expressed at all stages. A shift occurred from its 
basal localization to a more apical staining pattern in EAC.  
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(d)                                                                                (e)                                                   
Figure 5 ADAM mRNA expression in human samples of distal and proximal esophagus, 
representing GERD and EAC pathology at different stages, (a) ADAM9 (b) ADAM10 
(c) ADAM12 (d) ADAM17 (e) ADAM19.  * = ≤0.05 in ANOVA / Dunnett´s or 
Kruskal-Wallis / Dunn´s test comparisons between patients and controls, and ^ = 
p≤0.05 in paired t-test or Wilcoxon signed rank test comparisons between distal and 
proximal patient samples. Error bars indicate the standard error of mean. Values 
represent relative expression as compared to the expression in NCI-N87 cell line, 
corrected by GAPDH and beta actin expression. Reproduced and modified from 
Kauttu T, Mustonen H, Vainionpää S, Krogerus L, Ilonen I, Räsänen J, Salo J, 
Puolakkainen P. Disintegrin and metalloproteinases (ADAMs) expression in 
gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin Transl 
Oncol. 19:58-66, 2017. With permission of Springer.  
5.2 CIP2A and c-MYC expression in EAC 
Immune staining scores of CIP2A and c-MYC proteins relative to EAC and BE stages are 
presented in Figure 6. CIP2A expression was mainly cytoplasmic. The staining grade of 
both CIP2A and c-MYC in BE and EAC differed from that in control samples (p= 0.008 
and 0.030, respectively). Staining grade of CIP2A and c-MYC correlated with each other 
(R=0.21, p=0.018).  
Neither CIP2A nor c-MYC expression affected survival in Cox regression analysis. 
Among patients with the most advanced (stage IVA-B) tumors, CIP2A expression showed 
a trend towards poor prognosis (p=0.074).  
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 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
Figure 6 CIP2A (a) and c-MYC (b) expression in the normal esophageal squamous epithelium, 
in different stages of BE, and in different EAC stages. Data from Rantanen T, Kauttu 
T, Åkerla J, Honkanen T, Krogerus L, Salo J, Paavonen T, Oksala N. CIP2A 
expression and prognostic role in patients with esophageal adenocarcinoma. Med 
Oncol. 30:684, 2013. 
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5.3 Long-term effects of laser ablation for BE 
Laser ablation for BE with previous antireflux surgery had resulted in histologic 
eradication of IM in 15 patients (83%). After a mean follow-up of 7.9 years (range 2.7–
15.4 years), 10 patients (56%) had complete eradication of IM. Of those 15 patients with 
initial eradication of IM, 3 (20%) had a recurrence of macroscopic BE, and 5 (33%) had a 
recurrence of IM. A total of 6 patients (33%) had macroscopic BE, and 8 (44%) had IM 
detected histologically. The average change in BE length was -2.7 cm (range -6 to 4 cm). 
Neither dysplastic changes nor buried columnar tissue appeared. Fundoplication was 
determined as anatomically normal at endoscopy in 14 patients (82%). Of the 8 patients 
with IM detected at the control endoscopy, 3 had disrupted fundoplications, and one had 
partial gastrectomy with Roux-en-Y reconstruction. 3 patients (17%) were taking PPI 
regularly, and 3 occasionally.  
8-OhdG levels were increased both in the distal and proximal esophagus, 
compared to controls’ (Figure 7 a, b). SOD activity was increased in the distal esophagus, 
compared to controls’ (Figure 8 a), whereas MP activity and GSH level were normal 
(Figure 8 b, c). Microscopic esophagitis, presence of IM, or failure of fundoplication did 
not affect results. Two patients with microscopic esophagitis showed weak nuclear p53 
expression typical of inflammation. One patient showed Cdx2 expression in IM.  
  
(a)                                                                   (b) 
Figure 7 8-OHdG levels in the distal (a) and proximal esophagus (b) of patients treated with 
Nd-YAG laser ablation, and in controls. * p < 0.01, ** p < 0.001. The average 8-
OhdG-level in each group is given in brackets. Reproduced and modified from Kauttu 
T, Räsänen J, Krogerus L, Sihvo E, Puolakkainen P, Salo JA. Long-term results of 
ablation with antireflux surgery for Barrett's esophagus: a clinical and molecular 
biologic study. Surg Endosc. 26:1892-7, 2012. With permission of Springer.  
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(a)                                                                  (b) 
 
 
     (c) 
Figure 8 Activities of SOD (a) and MP (b), and GSH content (c) in the distal esophagus of 
patients treated with Nd-YAG laser ablation, and in controls. ** p < 0.001. The 
average SOD / MP / GSH -level in each group is given in brackets. Reproduced and 
modified from Kauttu T, Räsänen J, Krogerus L, Sihvo E, Puolakkainen P, Salo JA. 
Long-term results of ablation with antireflux surgery for Barrett's esophagus: a 
clinical and molecular biologic study. Surg Endosc. 26:1892-7, 2012. With 
permission of Springer.  
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5.4 EAC after antireflux surgery 
During 1987-2006, EAC incidence (as the standardized incidence ratio, SIR) after 
antireflux surgery was increased 9.2-fold (95% confidence interval 6.2-13.2) (men 9.3-
fold increase, women, 8.6-fold increase) compared to rates in the general population.  The 
annual number of EAC cases diagnosed in Finland during the study period increased 
(Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 EAC cases diagnosed annually in Finland during 1980-2006. 
Of the 53 EAC patients with a previous antireflux surgery, 39 were male. 19 
patients (36%) were smokers, but information on smoking status was available for only 24 
(45%). EAC was diagnosed on average at 10.1 years (range 0.5–25.6 years) after 
antireflux surgery; 32% of cases were diagnosed at 5 to 10 years after antireflux surgery, 
and 43% over 10 years after antireflux surgery. Less than half (40%) of the cases were 
diagnosed at endoscopic surveillance. Of the 38 patients with available GERD symptom 
data (72%), 89% had typical symptoms of heartburn or regurgitation, or both, and 79% 
had used either PPIs or H2RAs. BE was diagnosed before the antireflux surgery in 45% 
(one patient with non-specified dysplasia and one with HGD), and postoperatively or at 
EAC diagnosis in an additional 34%, leading to a total of 79% of the patients with 
histologically confirmed BE. Endoscopic esophagitis had been diagnosed in 41 (77%) and 
a hiatal hernia in 40 (75%) preoperatively. 
The type of antireflux surgery was fundoplication in 50 patients (15% 
laparoscopic, and 95%–among those 44 with available data–complete 360° 
fundoplications) and partial gastrectomy with Roux-en-Y reconstruction was performed 
on four (one combined with a fundoplication). Reoperations had been necessary in four 
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patients due to failure of the primary fundoplication. Fifteen patients (28%) underwent 
cholecystectomy, whereas in Finland during 1987-2006, 10% of all the patients with 
antireflux surgery underwent cholecystectomy. 
The state of the fundoplication was assessed by endoscopic findings, and anatomic 
failure was established with disruption, significant loosening or distal displacement of the 
fundoplication wrap. The assessment of antireflux function in all the patients was based on 
the combination of reflux indicators, and functional failure was established if the patient 
had disrupted anatomy, pathologic pH-monitoring, low LES-pressure at manometry, 
endoscopic esophagitis or regurgitation. Thirteen (26%) patients had anatomic failure, and 
they developed EAC later (mean 12.0 years) after antireflux surgery than did those 23 
(46%) with an anatomically intact fundoplication (mean 7.0 years), p=0.0069 (Figure 10 
a). Those 22 (44%) with a functional failure of the antireflux surgery also developed EAC 
later (mean 11.2 years) postoperatively than did those 15 (30%) with a functional anti-
reflux barrier (mean 6.4 years), p=0.015 (Figure 10 b). Hiatal hernia or widening of the 
hiatus closure was detected in 22 (44%) patients. Mean time interval to EAC diagnosis in 
those patients with partial gastrectomy and Roux-en-Y reconstruction was 13.5 years 
(range 8-25 years). Of the patients, 40% used PPIs or H2RAs at least occasionally 
postoperatively, and medication use was associated with neither anatomic nor functional 
failure of the fundoplication.  
 
 
 (a) 
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 (b) 
Figure 10 EAC cases diagnosed in Finland annually vs. the time interval from fundoplication to 
EAC, grouped according to the anatomic condition (a) and functionality (b). Figure 
10 b is reproduced and modified from Kauttu TM, Rantanen TK, Sihvo EI, Räsänen 
JV, Puolakkainen P, Salo JA. Esophageal adenocarcinoma arising after antireflux 
surgery: a population-based analysis. Eur J Cardiothorac Surg. 40(6):1450-4, 2011, 
by permission of Oxford University Press.  
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6 Discussion 
The decelerating increase in EAC incidence [141] suggests that either the prevalence of 
EAC risk factors is stabilizing, or their treatment or prevention has been successful. 
Evidence of GERD treatment and BE ablation in EAC prevention is controversial [34, 35, 
38-40, 206, 210]. Recently, surveillance of BE has resulted in a better prognosis [14, 15]. 
Indirect evidence of stabilized incidence and incidence-based mortality from local EAC 
also points towards the effectiveness of surveillance and treatment improvements [141]. 
Along with GERD, other important risk factors also contribute to EAC development, ones 
such as obesity and smoking. Overall prevalence of smoking has been declining [283], 
whereas overall body-mass index has been increasing [284]. Generally, people live longer, 
and the proportion of aged people increases, leading to increased EAC risk at population 
level. An accurate evaluation of GERD incidence trends is difficult, due to obscurity in the 
disease classification, but GERD incidence has increased, for example, over six-fold in the 
USA during 1975–2009 [141]. Whereas a wealth of evidence connects GERD to EAC, an 
important contradictory argument is that treatment of GERD does not seem prevent, or 
even effectively reduce, EAC risk. This is an important and unanswered question, and the 
answer is at least as complicated as is the spectrum of GERD.  
Our understanding of the pathophysiologic mechanisms causing GERD has during 
recent decades become greatly enhanced. At the same time, a considerable shift has 
occurred in treatment, with PPIs becoming the first-line treatment, due to their effective 
symptom control. However, the severity of GERD symptoms does not necessarily 
correlate with disease severity, as GERD symptoms are not often associated with 
endoscopic findings. Only 41% to 57% of patients with erosive reflux disease are 
symptomatic [12, 64]. To be able to answer the question of the role of effective GERD 
treatment in EAC prevention, both enhanced knowledge of the actual effects of GERD 
treatment on the pathophysiology of the disease and knowledge of the molecular events 
during development of BE and EAC are essential. Of great importance is also an 
understanding of the interplay between various risk factors, which to date is still an issue 
scarcely studied.  
6.1 ADAMs in GERD and EAC 
Development of EAC is a multifactorial process in which many risk factors probably act 
synergistically. ADAMs cleave many molecules associated in the signaling events of the 
tumor microenvironment [20]. Their action may also lead to decreased signaling capacity, 
as shown in pancreatic cancer cells [285]. Most studies report an increased expression of 
ADAMs in cancer. Likewise, in our study, no ADAM showed decreased expression in 
EAC in human samples. In this first study exploring ADAM expression also in GERD and 
BE, no clear progressive increase for any ADAM was apparent during the stages from 
esophagitis to EAC. 
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ADAM9 emerged as the most consistently increased molecule in EAC. In BE and 
dysplastic BE, ADAM9 was also increased at mRNA level. ADAM9 has been 
increasingly expressed, for instance, in EAC (at mRNA level) and in gastric cancer, 
esophageal squamous cell carcinoma, non-small cell lung cancer, and prostate cancer [21, 
22, 264, 269, 286].  Data mostly from cell lines indicate that ADAM9 promotes invasion 
and metastasis [287, 288]. Moreover, a gastric cancer cell-line study suggests a role for 
ADAM9 in gastric cancer progression and invasion, with hypoxia inducing its expression 
[289]. Data from human samples in non-small cell lung cancer, bladder cancer, and 
pancreatic ductal adenocarcinoma indicate that ADAM9 expression may be a prognostic 
marker associated with poorer prognosis [269, 290, 291]. Oxidative stress is implicated in 
the pathogenesis of GERD and EAC [251, 252], and ADAM9 may be a mediator of the 
invasiveness promoted by oxidative stress [265]. Recent studies show that ADAM9 may 
mediate the effects of microRNA 126 on cancer cell proliferation, migration, and invasion 
[286, 291]. Further studies of the role of ADAM9 in different stages of EAC development, 
and of its possible association with EAC stage and prognosis, are essential. 
Some ADAMs were increased in EAC only at mRNA level (ADAM12, ADAM17, 
ADAM19), which may be explained either by the lack of power due to the small number 
of patients in our IHC analysis or by the inability of our detection methods to capture 
these proteins. The opposite was observed for ADAM10, which was overexpressed only at 
protein level. All these molecules were previously found increased in EAC at mRNA 
level, with ADAM12 expression correlating with tumor grade [22]. Recently, ADAM10 
has been implicated in the mechanism for acquired resistance to the human epidermal 
growth factor receptor 2-antibody trastuzumab in EAC cell lines (OE19 and OE33) [292]. 
ADAM17 protein, detected by both western blotting and IHC, is increased in esophageal 
squamous cell carcinoma and also correlates with prognostic variables [293]. The 
participation of ADAMs in inflammation was manifested in our study, as ADAMs 12 and 
19 showed mRNA alterations in both esophagitis and EAC and may affect EAC 
development through inflammatory pathways. In severe macroscopic esophagitis, their 
expression was even more pronounced. ADAM19 is increased also in two other 
inflammatory conditions of the digestive tract: ulcerative colitis and Crohn´s disease 
[294]. ADAM12, on the other hand, is increased in the synovium of patients with 
osteoarthritis [295]. All these ADAMs showed increased expression in EAC, and this 
finding and its possible importance needs confirmation in further studies, with a greater 
number of protein samples. The role of ADAM12 and ADAM19 in inflammation-driven 
carcinogenesis seems especially interesting. 
Our patient groups included relatively few samples, leading to possible bias. 
Patients were also older and had a male predominance in contrast to the gender ratio of 
controls. The effect of age and other risk factors for EAC, such as obesity and smoking, on 
ADAM expression were not recorded, and therefore cannot be excluded. Disparities 
between the ADAM mRNA and protein expression, however, may also be due to post-
transcriptional modulation of ADAMs. An example of this is the regulation of ADAM9 
expression by microRNA 126 [286, 291]. ADAM10 and ADAM19 are also targets of 
microRNA regulation in cancer invasion and metastasis [296, 297]. At post-translational 
level, ADAMs are regulated by differing localization, processing, and kinase/phospatase 
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activity [20], underlining the importance of analyzing ADAM expression at both mRNA 
and protein levels. The possible roles of regulatory molecules such as ADAMS also need 
study in functional assays.  
6.2 CIP2A in EAC 
Along with ectodomain cleavage by proteases to activate signaling pathways, 
phosphorylation is a key regulatory element in cellular signaling. CIP2A, the inhibitor of 
protein phosphatase 2A, is an oncogene increased in many human cancers. In our study, it 
was abundantly expressed also in EAC, together with c-MYC. Their expression in the 
squamous mucosa was mild, while in BE and associated dysplasia, it was more 
pronounced. Few patients had BE or BE with dysplasia, and they were the patients who 
also had cancer. CIP2A expression in BE patients not progressing to cancer thus remains 
unknown. Because of the small number of BE patients with cancer, however, nor can any 
firm conclusions on their CIP2A expression be drawn. To assess this, a larger study 
comparing CIP2A expression between those BE patients who progress to EAC and those 
who do not would be needed. Squamous control tissue came also from the EAC patients, 
but tissue samples were very few, only 5, possibly leading to bias. CIP2A expression was 
mild in all the control samples. Previously, CIP2A expression has been found in only 20% 
of squamous tissue adjacent to esophageal squamous cell carcinoma, however [27].  
CIP2A expression was not associated with EAC prognosis. We had, however, a 
relatively small number of patients in each subgroup. Overall CIP2A-immunopositivity 
was high at 97.3%. A weakness of this study is its possible selection bias due to more than 
half of the originally screened patients dropping out due to insufficient tissue material; this 
may have also affected results. Another weakness is the study’s retrospective nature. 
CIP2A expression was not associated with stage, and stage was a strong prognostic factor. 
Patients with the most advanced disease (stages IVA-B) showed a trend towards even 
poorer prognosis based on positive CIP2A expression (p = 0.074).  
Many downstream targets of CIP2A are involved in carcinogenesis [278, 298], 
some of them with possible importance in EAC, like the survival- and growth-promoting 
protein kinase B (AKT) pathway (in activation of NF-κB) [299] and transcription factor 
E2F1, participating in both cellular progression and apoptosis, whose expression is 
associated with a positive effect on EAC survival [300]. Thus, the downstream effects of 
increased CIP2A expression in BE and EAC remain to be elucidated. The association of 
CIP2A expression with p53 [28, 279], one of the most promising predictors of neoplastic 
progression in BE [23], makes them candidates for further study together in BE. Our 
finding of frequent c-MYC expression in EAC is in line with previous findings (73-90%), 
whereas its overexpression has been reported to be less frequent in BE (37-50%) [274, 
275], possibly reflecting the fact that our BE patients were those who developed EAC. 
The effect of c-MYC on EAC prognosis has been unknown, although its amplification has 
been detected in one patient progressing to high-grade dysplasia after photodynamic 
therapy [301]. 
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6.3 Surgical treatment of GERD in preventing EAC – why does it 
fail? 
Abnormal reflux in GERD results from altered anatomic and physiologic properties of the 
esophagus and the proximal stomach [11]. Although the level of gastric acid secretion in 
GERD is mainly normal, and in ERD bile reflux plays a synergistic role with acid [73], 
PPIs offer good symptom control and heal esophagitis quite effectively. The significance 
of PPI effects, besides their acid suppression, is thus far unknown. Often inadequate PPI 
use and the consumption of PPIs by many patients after fundoplication–although often 
without objective evidence of recurrent reflux–may present confounding factors in studies 
exploring the GERD treatment efficacy. Patients with NERD who are on PPI therapy have 
higher symptom scores than do those with ERD [302]; GERD symptom severity seems to 
be a poor predictor of ongoing disease severity. Post-treatment symptoms may result from 
esophageal hypersensitivity, through the process of peripheral or central sensitization [55]. 
The link between EAC and GERD has mostly been established in studies based on GERD 
symptoms or in studies of BE patients, with the significance of erosive esophagitis less 
well studied. Possible interactions between risk factors, like between genetic alterations 
and GERD that combined may contribute to esophageal carcinogenesis [103], have thus 
far gone largely unstudied.  
In theory, fundoplication may be a better treatment method for GERD than is 
antireflux medication, because surgery reconstructs the defective antireflux barrier and 
also prevents duodenogastroesophageal reflux. In ERD and BE, bile reflux increases [63]. 
Fundoplication reduces TLESRs, and their association with reflux also in long-term 
follow-up (> 5 years postoperatively) [162]. However, no significant effect on cancer 
prevention has been observable, not even reduced risk in comparison to that with medical 
treatment [38-40]. No prospective randomized controlled trials have assessed the cancer 
risk after antireflux surgery; there is only one follow-up of a randomized controlled trial 
with insufficient power for analysis of EAC risk [38], and most of the studies have been 
retrospective cohort studies. In any one retrospective trial, important factors such as 
history of GERD, adequacy of medication use, other confounding risk factors (smoking, 
obesity, diet), and status of the fundoplication cannot be reliably determined. This was 
also a difficulty in our study, with incomplete information on factors related to GERD 
such as operative indications and inability to control for other risk factors. On the other 
hand, smaller case-control studies cannot be generalized to population level. Indications, 
operations, and results of antireflux surgery are variable, but it seems clear that at 
population level, antireflux surgery does not protect from EAC, a finding also supported 
by our study. According to one meta-analysis, antireflux surgery does not seem efficient 
for EAC prevention even in BE patients [189].  
The failure of fundoplication seems important in the progression of BE 
postoperatively [173, 190, 191], and this was corroborated by our study with a significant 
number of functionally failed fundoplications. EAC also appeared earlier after antireflux 
surgery in patients with an intact antireflux barrier than in those with a defective one. The 
failure rate was high in our study: an anatomic failure was detectable in 26% and a 
functional failure in 44%. Although this might reflect ineffective reflux inhibition as a risk 
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factor for EAC development, it may also reflect an overall high failure rate of 
fundoplication at population level at the time of our study. The difficulty in identifying 
those patients with true postoperative reflux is the negative association of objective 
recurrent reflux with symptoms and postoperative medication use; neither of these seems 
to predict failure, as detected by pH study [175, 176]. However, some studies suggest that, 
after antireflux surgery, symptoms requiring treatment or antireflux medication are risk 
factors for malignant progression [193, 194]. At population level, in order to reliably 
detect all the patients with ongoing abnormal reflux, virtually all patients, regardless of 
their symptoms, would have to be examined.  
 Our study also suggests that BE (both preoperatively and in total) and erosive 
esophagitis might be risk factors for post-fundoplication EAC. Despite our lack of a 
control group, which is a clear limitation of our study, the prevalence of preoperative 
endoscopic erosive esophagitis (77%) was more frequent than described in GERD (39%) 
[63]. Erosive esophagitis has raised EAC risk 2- to 5-fold, but this risk may be mostly 
attributable to BE [303, 304]. Of the patients with erosive esophagitis, 9% have developed 
BE in a 5-year follow-up [305]. In our study, total BE prevalance (79%), diagnosed at any 
time in the course of GERD, was more than earlier studies have detected at the time of 
EAC (30-62%) [87, 306]. At EAC diagnosis, the tumor may have overgrown the segment 
of IM from which it originated. BE is known to be heterogenic, and dysplasia often 
patchy. Therefore, a biopsy sampling error may account for some of the EAC cases 
occurring early after antireflux surgery. There might also exist an irreversible threshold for 
malignant transformation even in microscopically normal-appearing BE. Indeed, based on 
preliminary communication regarding in vitro cell-line data, the progression of BE cells, 
induced by acid and bile, occurred in stages, whereby after passing a certain limit, 
progression occurred although exposure to acid and to bile ceased [245]. At least in cases 
of EAC appearing a few years after antireflux surgery, carcinogenesis is likely to have 
already begun. BE may also harbor inherent procarcinogenetic factors, such as a low level 
of apoptosis [307]. After fundoplication, proliferative activity of the esophageal mucosa 
remains increased [308]. Oxidative stress of the distal esophagus is only partially reversed 
after antireflux surgery, and the proximal esophageal mucosa shows a persistently 
defective antioxidant capacity [257, 309].  
At present, no method allows determination of the phase in which treatment of 
GERD could halt development of EAC. Possibly, for certain individuals, fundoplication 
performed at a very early phase of GERD–which is normally not when antireflux surgery 
is performed–and remaining intact at long-term follow-up, might protect against EAC. 
Since many people with severe GERD and longstanding symptoms or mucosal changes do 
not progress to EAC, and given the propensity of fundoplications to be slowly disrupted in 
the long term, the possible protective effect of fundoplication would be at best very low. 
Even with an intact fundoplication, other risk factors for EAC may drive carcinogenesis. 
Very long follow-up times of 20, rather than 10 years, are needed to detect the true 
occurrence of EAC after antireflux surgery, as supported by our study results. At 
population level, the 9-fold increased EAC risk after antireflux surgery during long 
follow-up clearly shows that this surgery is not protective against EAC.  
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For the obese, laparoscopic gastric bypass with Roux-en-Y reconstruction has been 
recommended, based on its combined effects on acid reduction and weight control. Large-
scale studies would be necessary to find whether this operation has a cancer-preventive 
effect in the obese. Our small patient numbers having partial gastrectomy with Roux-en-
reconstruction, together with incomplete information on weight data for the majority of 
patients, allowed no reliable comparisons.  Theoretically, the bile diversion in the Roux-
en-Y procedure might improve the inhibition of bile reflux produced by fundoplication. 
After partial gastrectomy and Roux-en-Y reconstruction (combined with vagotomy and 
either fundoplication or Hill’s gastropexy), or after gastric bypass with Roux-en-Y 
reconstruction, regression of BE to the cardiac mucosa has been documented, with no 
progression to HGD or EAC detectable [167, 168].   
Cholecystectomy has been suggested to promote gastroesophageal reflux, 
especially duodenogastroesophageal reflux. Cholecystectomy was indeed nearly three 
times as frequent in our study patients (28%) as in the general Finnish population (10%). 
More-recent studies claim, however, that, after cholecystectomy, GERD symptoms 
decrease rather than increase, and that manometry and impedance-pH-monitoring show no 
increase in gastroesophageal reflux or in LES pressure [310, 311].  
6.4 Endoscopic eradication of BE 
For patients with BE, its eradication combined with anti-reflux treatment is another 
method aiming at EAC prevention. BE eradication is indicated for patients with HGD or 
early cancer, but not in BE without dysplasia. It is currently recommended also for 
patients with LGD persisting after PPI therapy [124]. Despite negative margins with 
endoscopic resection, and subsequent ablation of BE, intestinal metaplasia and dysplasia 
tend to reappear, and EAC may develop. The long-term effects of endoscopic therapy 
remain somewhat controversial, with many studies suggesting good outcomes in terms of 
the eradication of both IM and dysplasia or neoplasia [30, 31, 210], and others suggesting 
that HGD recurs in 14%, IMC in 11%, and IM in nearly 70% of cases at 5 years [206]. If 
eradication results are improving with growing experience and combined EMR, as 
suggested [207], eradication of BE might again become a treatment option for high-risk, 
non-dysplastic BE patients in the future, given its reasonably mild adverse effects. 
Eradication may not be needed if BE surveillance proves effective, however. Evidence of 
favorable results in surveillance: enhanced survival and discovery of early-stage cancers, 
is now accumulating [15].  
Milder pretreatment histology in ablation may lead to a smaller recurrence rate for 
IM, but results thus far are contradictory. BE progression status was associated with rate 
of IM recurrence in a large US registry study on RFA ablation, with older age, longer BE, 
and non-Caucasian race representing independent risk factors for recurrence–although the 
model did not include risk factors such as obesity and smoking [212]. In contrast, 
pretreatment histology did not affect a recurrence rate of 33% at two years in a US cohort 
study. [205]. A possible difference in recurrence rate between BE with or without 
neoplasia may be explainable by other existing risk factors such as obesity, reduced 
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female hormones, genetic factors, and already induced pro-carcinogenetic changes. Our 
recurrence rate of 20% for macroscopic BE and 33% for intestinal metaplasia at eight 
years is higher than that reported in most other studies, but with shorter follow-up times 
[30, 31, 210]. Of our 8 patients with IM found at follow-up, three had a disrupted 
fundoplication, and in two of these, eradication had initially failed. The patient with partial 
gastrectomy and Roux-en-Y reconstruction also had an initially failed BE eradication. Our 
study had a small number of patients, and other risk factors of BE progression could not 
be accounted for.  
The origin of EAC after ablation–residual or reappearing IM or buried glands 
under the neosquamous mucosa–is unclear. The role of residual or reappearing IM at the 
SCJ is also unclear. Studies show a considerable frequency of intestinal metaplasia with or 
without dysplasia at the SCJ after ablation (24-47%) [31, 205]. Development of dysplasia 
or EAC in that IM region clearly suggests malignant potential. Findings of residual BE or 
IM as risk factors for subsequent dysplasia or neoplasia are controversial [206, 213]. In 
our study, Cdx2 expression in the squamous mucosa was present in only one patient (with 
residual IM), although Cdx2 supposedly plays a role in inducing BE [41].  
Oxidative stress is involved in carcinogesis and inflammation and is also increased 
in Barrett’s esophagus [252, 254]. In our study, oxidative DNA damage, measured as 8-
OhdG level, was increased both in the distal neosquamous and proximal squamous 
mucosa. Earlier, 8-OHdG levels have been found to be increased both in the BE and in the 
proximal esophagus of those patients [251], suggesting some already acquired or inherent 
characteristic in BE patients. In GERD patients, even after successful antireflux surgery, 
antioxidative capacity in the proximal esophagus, studied as GSH content and SOD 
activity, seems reduced [309]. In contrast to 8-OHdG, levels of MP and GSH were 
unchanged in our study, contrary to earlier findings of their altered expression in GERD 
[252, 254, 256]. SOD activity was increased in our patients’ neosquamous mucosa. It has 
been increased in dysplastic BE [252] and increased or unchanged in BE [252, 254], but 
also, conversely, decreased in esophagitis and in BE, with SOD expression decreased in 
dysplastic BE and EAC [255, 256]. In a rat model, exogenous SOD has been protective of 
BE and EAC [312]. Interestingly, PPI treatment may raise the SOD level reduced in BE 
[313]. The increased SOD level in the neosquamous mucosa possibly may serve as a 
protective factor. Thus, evidence exists of both ongoing oxidative stress and of normalized 
parameters after ablation. A possible confounder in our analyses was the more proximal 
location of the distal and proximal esophageal control samples as compared to patient 
samples, because the esophageal acid exposure becomes greater more distally. MP and 
GSH levels were, however, normal even more distally than in controls.  
We have shown that the ablation of BE leads to at least partially normalized 
oxidative stress in the neosquamous mucosa in a long follow-up. No characteristics 
suggesting malignant development emerged. Laser ablation is no longer used, but future 
studies with RFA are likely to clarify its potential benefit in treating benign BE. To further 
enhance the efficacy of BE surveillance and of patient selection for different treatment 
methods, a need clearly exists for molecular studies in addition to known clinical risk 
factors in finding predictive markers to identify patients at greatest risk for BE 
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progression. In these studies, the effect of EAC risk factors such as obesity, smoking, and 
male sex should also be taken into account by means of multivariate analysis.  
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7 Summary 
EAC remains a lethal malignancy despite advances in its diagnosis and treatment. Among 
its risk factors, GERD, obesity, and smoking remain prevalent, and the population is 
growing older. Treatment of GERD or BE has not led to a decrease in EAC incidence. 
Few patients with GERD or BE exhibit malignant progression, which is likely to result 
from the interplay of various genetic and environmental factors and may be driven 
independent of already cured pathologic reflux. It is evident that treatment of GERD alone 
cannot halt the progression to EAC.  
Despite extensive research, the molecular pathogenesis of the Barrett’s metaplasia–
dysplasia–EAC sequence has not been shown to feature any distinct pathway. Many 
molecular and genetic alterations show associations with EAC in individual studies. Yet it 
seems that it is rather a set of those alterations that predicts risk for EAC. We studied 
molecules being of possible importance for EAC development. Of these, ADAM9 
emerged as the most consistently increased molecule in EAC, with increased mRNA 
expression appearing already in BE with or without dysplasia. ADAMs possess various 
signaling capabilities, and their altered expression in GERD, BE, and EAC suggests that 
larger-scale studies and functional assays are needed to elucidate their role in EAC 
development. Other molecules that we studied, the oncogenes CIP2A and c-MYC, 
although abundantly expressed in EAC, had no impact on EAC prognosis. The role of 
CIP2A in BE and in the progression of BE remains for further study. 
Efforts to eliminate the cancer risk of BE by ablation have proven ineffective. With 
the techniques developed, and with the addition of endoscopic resection, results have 
improved, and EAC risk may be diminishing. IM tends to recur even with effective reflux 
inhibition, however, in a significant number of patients–33% in our study at long-term 
follow-up after BE laser ablation combined with antireflux surgery, but with no evidence 
of malignant development. Oxidative stress, an important factor in the derangement of 
tissue homeostasis predisposing for cancer, was in part normal and in part elevated. The 
elevated levels of 8-OHdG suggest some kind of similarity in tissue homeostasis between 
neosquamous mucosa and BE.  
Antireflux surgery can effectively control GERD symptoms. A considerable 
number of fundoplications tend to fail during long-term follow-up, however. In our 
detailed analysis of EAC cases after antireflux surgery, EAC occurred a long time after 
even successful antireflux surgery. With a well-working antireflux barrier, however, EAC 
occurred earlier postoperatively than with a failure. As our patient numbers were small, 
the role of chance or other risk factors can be neither evaluated nor excluded. The total 
proportion of BE diagnosed (79%) and the prevalence of endoscopic esophagitis 
preoperatively (77%) were high. Even though reflux inhibition may play a role in 
preventing GERD-associated malignancy, it cannot protect from other EAC risk factors or 
possibly lead to a halt in already initiated pro-carcinogenic pathways. Antireflux surgery 
should not be recommended as protective against EAC, since EAC risk remained elevated 
9-fold.  
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8 Conclusions 
1. The expression of members of the ADAM-molecule family was altered in 
esophagitis, in BE, in BE with dysplasia, and in EAC, although no clear 
progressive trend in ADAM expression appeared along this sequence. ADAM9 
was most constantly overexpressed, and further studies on its possible role are 
necessary.  
 
2. The oncogene CIP2A, along with c-MYC, was frequently expressed in EAC. 
Neither the expression of CIP2A nor that of c-MYC correlated with survival, 
however.  
 
3. BE occurred in about one-third of the patients at the 8-year follow-up after BE 
laser ablation combined with antireflux surgery. IM occurred in 44% of the 
patients. No signs of malignant progression appeared, however. Oxidative DNA 
damage was elevated both in the distal and proximal esophagus.  
 
4. EAC risk was approximately 9 times as high after antireflux surgery as in the 
general population. Endoscopic esophagitis prior to antireflux surgery, BE, and the 
failure of antireflux surgery were frequent findings. Antireflux surgery cannot be 
considered protective against EAC. 
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